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ABSTRACT
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HIV-1 enters the CNS soon after initial systemic infection. HIV-1 can induce a wide range of
neurological deficits, collectively known as HIV-1-associated neurocognitive disorders (HAND).
Mature neurons are not infected by HIV-1; instead, infected and/or activated glial cells release
various viral and cellular factors that induce direct and/or indirect neuronal toxicity, leading to
HAND. Injection drug abuse is a significant risk factor for HIV-infection, and opiate drug
abusers show increased HIV-neuropathology, even with anti-retroviral treatments. Our previous
work has largely modeled HIV-neuropathology using the individual viral proteins Tat or gp120,
with murine striatal neurons as targets. To model disease processes more closely, the current
study uses supernatant from HIV-1-infected cells.
Supernatant from HIV-1SF162 (R5-tropic)-infected differentiated-U937 cells (HIV+sup) was
collected and p24 level was measured by ELISA to assess the infection. We assessed HIV+sup
effects on neuronal survival and neurite growth/pruning with or without concurrent exposure to

morphine, an opiate that preferentially acts through µ-opioid receptors. Effects of HIV+sup ±
morphine were assessed on neuronal populations, and also by time-lapse imaging of individual
cells. HIV+sup caused dose-dependent toxicity over a range of p24 levels (10-500 pg/ml).
Significant interactions occurred with morphine at lower p24 levels (10 and 25 pg/ml). In the
presence of glia, selective neurotoxic measures were significantly enhanced and interactions with
morphine were also augmented. Importantly, the arrest of neurite growth that occurred with
exposure to HIV+sup was reversible unless neurons were continuously exposed to morphine.
Thus, while reducing HIV-infection levels may be protective, ongoing exposure to opiates may
limit recovery.
During early stage of HIV-infection R5-tropic viruses are predominant, but during later stages of
disease X4-tropic viruses are more predominant; co-receptor usage switch from CCR5 to
CXCR4 is crucial in disease progression to AIDS. Some previous studies have shown that drugs
of abuse interact with virus or viral proteins in strain/tropism-dependent manner. Therefore, we
also assessed neurotoxic effects and interactions with opiates by supernatant from HIV-1LAI (X4tropic)-infected H9 cells. Neurotoxic effects and the interactions with opiates of HIV-1LAIsupernatant are quantitatively similar to that of HIV-1SF162. Surprisingly, the cytokine/chemokine
release profile of HIV-1LAI-infected H9 cells is similar to that of HIV-1SF162-infected U937 cells.
Only in the presence of glia, HIV-1LAI virion induced neurotoxic effects, but no interactions with
morphine were seen. Also our studies have shown that HIV-1LAI virions are slightly more
neurotoxic than HIV-1SF162. Altogether, largely our results suggest that HIV+sup mediated
neurotoxicity and the interactions with opiates are majorly attributed to cytotoxic factors released
from infected and activated cells instead of viral strain specific factors.

Although there is a correlation between opiate drug abuse and progression of HAND, the
mechanisms that underlie interactions between HIV-1 and opiates remain obscure. Previous
studies have shown that HIV-1 induces neurotoxic effects through abnormal activation of
GSK3β. Interestingly, expression of GSK3β has shown to be elevated in the brains of young
opiate abusers suggesting that GSK3β is also linked to neuropathology seen with opiate abusing
patients. Thus, we hypothesized that GSK3β activation is a point of convergence for HIV- and
opiate-mediated interactive neurotoxic effects. Cultures of striatal neurons were treated with
HIV+sup (R5-tropic), in the presence or absence of morphine and GSK3β inhibitors. Our results
show that multiple GSK3β inhibitors significantly reduce HIV-1-mediated neurotoxic outcomes,
and also negate interactions with morphine that result in cell death. This suggests that GSK3βactivation is an important point of convergence and a potential therapeutic target for HIV- and
opiate-mediated neurocognitive deficits.

CHAPTER 1
Introduction

HIV/AIDS
Epidemiology of HIV/AIDS
Human immunodeficiency virus (HIV) infects immune system cells, primarily CD4+ T cells and
monocytes/macrophages. HIV infection dysregulates normal immune system functioning and
leads to acquired immunodeficiency syndrome (AIDS) [1-3]. Worldwide about 35.3 million
people are infected with HIV. In 2012, 2.3 million people were newly infected with HIV, and 1.6
million died due to AIDS [4]. Due to limited access to combination antiretroviral therapy
(cART), AIDS pandemic continues to spread unchecked in many underdeveloped countries; subSaharan Africa is badly affected region, where around 25 million people are living with HIV
infection. In 2012, in these countries nearly 1.6 million people were newly infected with HIV
and 1.2 million died due to AIDS. AIDS epidemic has eroded the socioeconomic stability of
these countries.
HIV genome and life cycle
HIV has been characterized into two types, HIV type 1 (HIV-1) and type 2 (HIV-2). HIV-1 is
relatively more pathogenic and thus is spread worldwide, while HIV-2 is relatively less virulent
and thus is restricted to limited parts of the world [5, 6]. HIV-1 has single stranded RNA genome
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consisting of 9 genes. The gag genomic region encodes for gag polyprotein, which is mainly
processed to p17 (matrix protein, MA), p24 (capsid protein, CA), p7 (nucleocaspid protein, NC),
and p6 proteins, by the viral protease. The pol gene encodes for reverse transcriptase (RT),
RNase H, integrase and protease. The env gene encodes for precursor glycoprotein gp160, which
is processed to surface glycoprotein gp120 and transmembrane glycoprotein gp41, by furin, a
host cell protease. Remaining 6 genes (tat, rev, nef, vpr, vif, vpu) encode for regulatory proteins,
involved in regulation of viral replication and release [3, 7-9].
HIV-1 surface glycoprotein gp120 binds/interacts to CD4 and a co-receptor, usually either C-C
chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) on the surface
of host cells. After binding/interaction, conformational changes in gp120 and gp41 enable virus
to fuse with host cells and release its genetic material into host cells. RT with help of host cofactors transcribes DNA from RNA template by process called reverse transcription. Integrase
integrates reverse-transcribed viral genome (DNA genome) into host chromosome. Following
integration, the virus uses host cell machinery to transcribe and/or translate its genetic material
and proteins. The Viral protease processes viral precursor proteins. Viral proteins and genetic
materials assemble at the host cell membrane and bud out as new virions, ready for next cycle of
infection. In some cases, following integration into the host genome, virus can remain latent for
prolonged periods [3, 7-9].
HIV-1 tropism
The preference of HIV-1 gp120 for the co-receptors, either CCR5 or CXCR4, defines viraltropism [10-13]. M-tropic (macrophage/monocyte tropic, R5-tropic) strains of HIV-1 use βchemokine receptor, CCR5, to attach to host cells, and thus they mainly infect monocytes and/or
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macrophages. T-tropic (T-cell tropic, X4-tropic) strains have preference for α-chemokine
receptor, CXCR4, and thus they mainly infect CD4+ T cells. Some strains of HIV-1 do not have
preference for either CCR5 or CXCR4, and are known as dual-tropic (X4R5-tropic) strains.
Previous studies have shown that also some other chemokine receptors, such as CCR2, CCR3
and C-X3-C chemokine receptor 1 (CX3CR1, fractalkine receptor), can serve as co-receptors for
viral attachment/binding at host cell surface [14-18].

NeuroAIDS
Invasion of HIV-1 into CNS
HIV-1 not only disrupts normal immune system functioning, but can also induce neurological
complications, known as neuroAIDS. The blood brain barrier (BBB) is a tight, cohesive barrier
between blood and brain. The BBB regulates influx of selective compounds from blood in
capillaries to brain parenchyma, important for homeostasis and proper functioning of the brain
[19-21]. Also the BBB protects central nervous system (CNS) from many infections and toxic
insults in blood/plasma. Unlike a variety of blood-borne insults, HIV-1 overcomes this tight
barrier and can invade the brain. HIV-1 can enter into the CNS soon after an initial systemic
infection [22-24]. The exact route/mechanism for HIV-1 entry across BBB is not known. There
are three hypotheses for route/mechanism of viral infiltration into CNS [22, 25]. The first
hypothesis suggests that HIV-1 may invade into CNS as a passenger within infected leukocytes,
which normally traffic across the BBB as a part of immune surveillance of the brain, known as
‘trojan horse’ hypothesis [26-28]. The second hypothesis suggests that activated and/or infected
immune cells release various cytokines/chemokines and viral proteins, which can disrupt BBB
integrity [29-32]. Thus, cell free virus particles may cross through compromised BBB and invade
3

into CNS. Alternatively, studies in cell cultures have shown that brain microvascular endothelial
cells (BMVECs) can internalize virus particles into intracellular vacuoles, traffic these vacuoles
via transcytosis, and release them at other side of the barrier [33-35]. Thus, it can be predicted
that HIV-1 may traverse the BBB via transcytosis through BMVECs. The third hypothesis
suggests that HIV-1 may invade into CNS via transmission by infected BMVECs because some
in vitro studies have shown that these cells are capable of transmitting virus to other cells by
direct cell-to-cell contact [36].
HIV-1 infection of cells in the brain
The Perivascular region of the brain is closely interfaces with the periphery, thus it comes in
early and direct contact with HIV-1-infected leukocytes and/or free virus particles that cross
through the BBB. Cells in this region of the brain, mainly perivascular macrophages, microglia
and astrocytes, are the major site of viral infection. Unlike other resident cells within the brain,
microglia are derived from mesoderm; microglia are also known as immune component of the
brain [37-39]. Macrophages and microglia express CD4 and CCR5, the major receptor and coreceptor for HIV-1 entry [40-42]. Various studies in cell cultures have shown that primary
macrophages and microglia are productively infected with HIV-1 [43-46].
Markers of viral infection, proteins and nucleic acids, have been detected in GFAP positive
astrocytes [47-50], suggesting that these cells can be infected with HIV-1. Several in vitro
studies with primary cells and tumor derived cell lines have confirmed that astrocytes can be
infected with HIV-1 [51-53]. However, after initial acute productive infection their viral
production is reduced to very low or undetectable levels [52, 54]. But virus production in
persistently infected astrocytes can be transiently activated by treatment with pro-inflammatory
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stimuli [52, 54, 55]. Also, it has been shown that persistently infected astrocytes initiate viral
production in co-cultured monocytes/macrophages and T-cells [52, 54, 56]. Thus, it can be
concluded that astrocytes act as a viral reservoirs.
Other resident cells of the CNS, oligodendrocytes and neurons, are rarely infected with HIV-1.
Very few studies have shown that these cells get infected [49, 57], while various other studies
did not detect any markers of HIV-1 infection in these cells [47, 58, 59]. Some in vitro studies
have shown that these cells can be infected with HIV-1 [60, 61], but it is a nonproductive
infection.
HIV-1-mediated neurotoxicity
Though HIV-1 induces profound changes in neuronal morphology, function and survival, the
virus itself rarely infects neurons [22, 47, 49, 58]; instead, viral proteins directly cause neuronal
damage or infected and/or activated glial cells produce cellular factors that drive secondary
toxicity in neurons, known as bystander effects [22, 62-65].
‘Direct injury’ hypothesis suggests that HIV-1 proteins, mainly transactivator of transcription
(Tat), gp120, negative regulatory factor (Nef) and viral protein R (Vpr), directly cause neuronal
damage or death without requiring the intermediary functions of non-neuronal cells [22, 62, 63].
Various studies using primary neuron and neuroblastoma cell line cultures have shown that
individual viral proteins induce toxicity including neurite degeneration and cell death [66-74].
However, in most of these studies the concentrations of viral proteins used were well above the
levels thought to be present in brains of HIV-1-infected patients [62, 63, 75]. Thus, we need to
be cautious when extrapolating results from these in vitro studies to actual human disease
settings.
5

‘Indirect injury’ or ‘bystander effects’ hypothesis suggests that cellular factors including
cytokines, chemokines, excitotoxic factors and free radicals, released from infected and/or
activated non-neuronal cells cause neuronal toxicity [22, 62, 63]. Several studies have shown that
infected and/or activated non-neuronal cells, mainly perivascular macrophages, microglia and
astrocytes, release various pro-inflammatory and/or neurotoxic factors including tumor necrosis
factor- α (TNF-α), interleukin-1β (IL-1β), IL-6, transforming growth factor-β (TGF-β)
interferon-γ (IFN-γ), fractalkine (CX3CL1), monocyte chemotactic protein-1 (MCP-1; CCL2),
RANTES (CCL5), matrix metalloproteinases (MMPs), arachidonic acids, glutamate, cysteine,
quinolinic acid (QA), nitric oxide (NO), free radicals etc. [22, 62, 63, 76-84]. Virus and/or viral
factors are also known to disturb neuron supportive functions of glia [51, 85, 86], which may
exacerbate neuronal damage.
As available data support the role for both, ‘direct’ and ‘indirect’ injury hypotheses, two
hypotheses/mechanisms might coexist. But in in vivo settings where neurons are in continuous
contact/communication with glia, the ‘indirect injury’ hypothesis seems to predominate [62, 63].
Synaptodendritic degenerative changes are thought to be the major substrate underlying HIV-1
related neurocognitive impairments. At least during the early stage of disease, synaptodendritic
changes are more predominant than cell death; in HIV-1-infected individuals the degree of
neurocognitive deficits is closely correlated to degeneration of synaptodendritic structures [8791]. Initial damage at synapses and dendrites may culminate into cell death; postmortem analyses
of brains of HIV-1-infected patients have shown evidence for neuronal death [92-95].
Though HIV-1 rarely, if ever, infects mature neurons, there is some evidence that neural
progenitor cells may be permissive to infection [96]. HIV-1 and gp120 are known to decrease

6

proliferation and/or differentiation capacity of neural progenitor cells [97, 98]. It is also reported
that number of proliferating cells in the hippocampus of HIV-1-infected patients is reduced [97].
Thus, it can be predicted that HIV-1 causes neurocognitive deficits not only by damaging
existing neurons but also by impairing neurogenesis [99].
HAND
HIV-1 can induce a wide range of CNS deficits, including cognitive decline, personality
changes, motor deficits and dementia, collectively known as HIV-1-associated neurocognitive
disorders (HAND) [100-104]. Nearly 50% of HIV-infected patients experience HAND [88, 105107]. Neurological impairments tend to be milder during early phase of HIV-1 infection, but
severity of HAND upsurges with disease progression [108-110]. The occurrence and severity of
HAND varies among HIV-infected patients; it may be because of differences in the individual’s
genetic control of immune system [103]. There are three diagnostic terms commonly used to
describe the severity of HAND [88, 104]: (a) asymptomatic neurocognitive impairments (ANI):
refers to mild neurocognitive deficits, do not interfere with patients’ everyday functioning; (b)
mild neurocognitive disorders (MND): refers to mild to moderate neurocognitive impairments,
interfere modestly with everyday functioning of patients; (c) HIV-associated dementia (HAD):
refers to moderate to severe neurocognitive impairments, markedly disturb patients’ day-to-day
functioning, these patients are incapable of living independently.
cART has markedly controlled systemic HIV-infection, and has improved the health status of a
large segment of patients [105, 111, 112]. Although cART has reduced the overall severity of
neurocognitive disorders in HIV-1 patients, the prevalence of HAND remains same [88, 105107, 111, 113]. The persistence of relatively high rates of CNS disease is likely due to a
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combination of longer patient survival, the relatively poor CNS penetrance of most antiretroviral
drugs [88, 114], and their neurotoxic effects [115, 116]. Inhibiting viral replication in periphery
by cART can partially reverse neurocognitive deficits [117, 118]. However, some patients who
have responded positively to early cART with time have reverted back and are showing
continued neurocognitive decline [119, 120]. In some cART receiving patients, although viral
replication in the periphery is significantly controlled, viral loads in the CSF are unchecked, a
phenomenon called CNS escape [121-123]. In some patients, even if the CNS viral load is
extremely low or undetectable, neurodegeneration can still occur in response to viral proteins,
such as Tat, that are released from cells even when viral replication has been inhibited [124].

HIV and Opiate Drugs of Abuse
Illicit drug abuse is a significant risk factor for HIV-transmission due to sharing of contaminated
needles and unsafe sexual activities. Nearly 30% of HIV-infected patients have history of drug
abuse, which frequently include opiates [125-127]. Other than illicit drug abuse, a large subset of
HIV+ patients are exposed to opiates for treatment of AIDS-related chronic pain syndromes.
Opiates by themselves are known to affect normal immune system function, including antibody
production, monocyte and T-cell functioning and natural killer (NK)-cells cytotoxicity [126,
128-130]. Opiates enhance immune cell inflammation and also increase expression of cytokine
receptors including CCR5 and CXCR4 [131-134], co-receptors for HIV-1-entry. Morphine, an
opiate that preferentially acts through µ-opioid receptors (MORs), enhances HIV-1
replication/expression in phytohaemagglutinin (PHA)-activated cultured human peripheral blood
mononuclear cells (hPBMCs) [135]. Chronic morphine treatment of simian immunodeficiency
virus (SIV)-infected rhesus macaques has shown to cause increase in viral replication, increased
8

rate of viral mutation and tolerance to azidothymidine (AZT or Zidovudine), an antiretroviral
drug, and decrease in life span of infected animals [131, 136-138]. Thus, it is likely that opiate
abuse not only increases risk of HIV-infection but also accelerates disease progression to clinical
AIDS.
Since opiate drugs of abuse themselves are known to induce neurotoxic/neuropathological
effects, such as blood brain barrier (BBB) breakdown, immune and glial cell activation, neuronal
damage etc. [139-144], it can be predicted that opiate drugs of abuse will exacerbate HIV-1associated pathogenesis in CNS. Opiates can interact directly to aggravate HIV-1-mediated
neurodegeneration, or they can act indirectly via exacerbating HIV-1-mediated glial cell
inflammation [125, 145-156]. Opiate drug abusing HIV+ patients are more susceptible to develop
HIV encephalitis (HIVE), which may lead to HAND [157-159]. The severity of neurological
deficits in opiate drug abusing HAND patients have been shown to be elevated compared to nondrug abusing patients [160-162].

GSK3β
Glycogen synthase kinase 3 (GSK3) was first identified as a regulator of glycogen metabolism;
inactivating phosphorylation of glycogen synthase by GSK3 is a central regulatory process in
glycogen biosynthesis [163-166]. GSK3 is a multifunctional serine/threonine kinase which is
ubiquitously expressed in eukaryotes. GSK3 exists in two highly homologous isoforms, α and β.
Both isoforms are highly conserved within their kinase domain; GSK3β is smaller, consists of
482 amino acids, while GSK3α additionally contains glycine-rich N-terminus extension [163,
165, 167-169]. Both isoforms are widely expressed in all tissues; however, in the brain GSK3β is
present in high abundance. Widespread expression of GSK3β in the brain suggests that it plays a
9

vital role in various neuronal signaling pathways. GSK3β is known to be an important player in
regulation of CNS development; it plays a critical role in neurogenesis, neuronal migration,
neuronal polarization, and axon growth and guidance [163, 166, 167, 169-171].
GSK3β is a constitutively active enzyme. Various kinases are known to phosphorylate GSK3β at
Ser-9 and thereby reduce its enzyme activity, including Akt (also known as protein kinase B;
PKB), p90 ribosomal s6 kinase (p90rsk), protein kinase A (PKA; also known as cyclic AMPdependent protein kinase) and protein kinase C (PKC). On the contrary, phosphorylation of
GSK3β at Tyr-216 by ZAK1 or Fyn increases its enzyme activity [163, 165, 169, 172, 173].
Various growth factors induce their neurotrophic effects via reducing the activity of GSK3β by
phosphorylation at Ser-9, including fibroblast growth factor 1 (FGF1), FGF2, insulin growth
factor 1 (IGF-1), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF);
while pro-apoptotic stimuli increase GSK3β activity via phosphorylation at Tyr-216 [163, 165,
173, 174].
GSK3β plays a crucial role in regulating functioning of various structural, metabolic and
signaling proteins in neurons including tau, MAP2, β-Catenin, activator protein 1 (AP-1), cyclic
AMP response element binding protein (CREB), nuclear factor-kappa B (NF-κB), heat shock
factor-1 (HSF-1) and others. These signaling proteins regulate a variety of cellular functions
including neuronal plasticity, gene expression and cell survival [163, 165, 166, 175].
Dysregulated GSK3β activity appears to be operant in various neuropathological conditions,
including Alzheimer’s disease, Parkinson’s disease, schizophrenia, autism and bipolar mood
disorder, and pharmacological inhibition of GSK3β ameliorate these diseases [163, 169, 173,
175-183].
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Role of GSK3β in HIV-1-mediated neurotoxicity
Various studies with neurons in cultures as well as with animal models have shown that HIV-1
induces neurotoxic effects via increase in the GSK3β activity, and the GSK3β inhibitors
ameliorate these toxic effects [174, 184-188]. The pathways through which HIV-1 induces
GSK3β activation are unclear. But the mechanisms through which GSK3β-activation promotes
neuronal damage mainly include β-Catenin and tau phosphorylation [184, 185]. β-Catenin is an
immediate downstream target of GSK3β; active GSK3β phosphorylates and thereby initiates
rapid ubiquitin-mediated degradation of β-Catenin, which otherwise positively regulate cell
survival and neurite outgrowth [173, 175, 189-191]. Tau-hyperphosphorylation has been
associated with neurodegenerative disorders, including Alzheimer’s disease [192-194]. GSK3β is
a principal tau-kinase [195-197]. Tau-hyperphosphorylation causes microtubule cytoskeleton
destabilization, leads to neurite degeneration. In addition to β-Catenin and tau, GSK3β regulates
the functioning/stability of various structural and signaling molecules that appears to play roles
in cell death and neurite damage [165, 175].
Recent studies have identified GSK3β as a central mediator of pro-inflammatory processes in
immune cells, including microglia [169, 198-200]. Thus, it is likely that GSK3β-activation may
play role in HIV-1mediated immune and glial cell activation, and the release of proinflammatory cytokines, leading to ‘bystander’ neuronal damage. A recent study by Kehn-Hall et
al. has shown that 6BIOder, a novel GSK3β-inhibitor, inhibits HIV-1 replication [201],
suggesting that GSK3β-activation may play a role in viral propagation.
Taken together, these studies support a central role of GSK3β-activation in HIV-1-mediated
neurotoxicity. In accord with these studies, several pilot clinical trials have demonstrated
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improvements in neuropsychological performance in HAND patients treated with GSK3β
inhibitors as adjunct therapy with stable cART [202-204]. Thus, it can be concluded that GSK3βmediated signaling pathways are potential therapeutic target in treatment of neuroAIDS.
Role of GSK3β in opiate-mediated neurotoxicity
Results from some previous studies have conflict regarding whether opiates induce GSK3β
activation or inactivation; some studies have shown that opiates induce GSK3β activation [205207], while some have shown that they inactivate it [208, 209]. Altogether, from these studies it
can be inferred that opiates induce dose- and time-dependent effects on GSK3β activity; acute
activation of MORs inactivates GSK3β by inducing phosphorylation at Ser-9 via
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, while chronic activation of MORs
induces GSK3β activation by inducing phosphorylation at Tyr-216, may be through elevation in
cytosolic Ca2+ [205].
Studies from brains of opiate abusing patients suggest a role of GSK3β-mediated signaling
pathways in opiate-associated neuropathology. The accelerated deposition of
hyperphosphorylated tau that occurs in the CNS of young opiate abusers [141, 142] is likely
related to elevated GSK3β expression [141] since GSK3β is a principal tau kinase [195-197].
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CHAPTER 2
Morphine Enhances HIV-1SF162-Mediated Neuron Death and Delays Recovery of Injured
Neurites
(This chapter has been published as an article; PLoS ONE 9(6): e100196.
doi:10.1371/journal.pone.0100196)

Introduction
Human immunodeficiency virus-1 (HIV-1) disrupts normal immune system function and leads to
acquired immunodeficiency syndrome (AIDS). HIV-1 can also induce a wide range of central
nervous system (CNS) deficits, collectively known as HIV-1-associated neurocognitive disorders
(HAND). HIV-1 enters the CNS soon after initial systemic infection [22, 24]. It is widely
believed that virus penetrates the CNS within infected monocytes and lymphocytes [22, 210],
which normally traffic across the blood-brain barrier (BBB) as a part of immune surveillance of
the brain. Mature neurons are not infected by HIV-1; instead, infected and/or activated glial cells
release various viral and cellular factors that induce direct and/or indirect neuronal toxicity,
leading to HAND [22, 65, 88, 211, 212]. Combination antiretroviral therapy (cART), which
controls systemic HIV-infection, has improved the health status of a large segment of patients
[105, 111, 112]. Although cART has reduced the overall severity of neurocognitive disorders in
HIV-1 patients, the prevalence of HAND remains at approximately 50% [88, 105-107, 111]. The
persistence of relatively high rates of CNS disease is likely due to a combination of longer
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patient survival, the relatively poor CNS penetrance of most antiretroviral drugs [88, 114], and
their neurotoxic effects [115]. Even if the CNS viral load is extremely low or undetectable,
neurodegeneration can still occur in response to viral proteins, such as transactivator of
transcription (Tat), that are released from cells even when viral replication has been inhibited
[124].
Injection drug abusers are at high risk of acquiring HIV-infection due to sharing of contaminated
needles and unsafe sexual behavior. Nearly 30% of HIV-infected patients have a history of
injection drug abuse involving opiates [125, 127]. Additionally, a subset of HIV+ patients is
exposed to opiates through their legitimate use for treatment of AIDS-related chronic pain
syndromes. As opiates by themselves are known to induce immunomodulatory or
immunosuppressive effects, both in the periphery and CNS [132, 140], it is hypothesized that
they may enhance virus spread or otherwise exacerbate disease processes. Experimental evidence
also suggests that opiates can interact with HIV-1 or HIV-1-proteins directly on CNS cells and
tissues [125, 145, 147-151, 153]. Among patients with HIV-1 infection, those who also abuse
opiate drugs show faster progression to AIDS and more severe neurocognitive deficits [160162].
Many previous studies have modeled HIV-neuropathology using individual viral proteins, such
as Tat, glycoprotein 120 (gp120), and others. However, the CNS of HIV-infected patients is not
only exposed to individual viral proteins, but instead to all cytokines/chemokines and other
cellular products, viral proteins and virus particles released from infected and/or activated cells.
Thus, to more closely model HIV-1-mediated neurotoxicity, we have used supernatant from
HIV-1SF162-infected differentiated-U937 cells (HIV+sup). The R5-tropic HIV-1SF162 strain was
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used since R5-tropic (monocyte/macrophage-tropic) viruses are predominant in cerebrospinal
fluid (CSF) and CNS parenchyma [213, 214].
Multiple outcome measures were studied after HIV+sup ± morphine treatments, including both
cell death and neurite degeneration. Studies in the presence of glia allowed us to distinguish
between direct and indirect neurotoxicity. Our results indicate that morphine worsens selective
neurotoxic effects of HIV, and that glycogen synthase kinase-3β (GSK3β) signaling may be a
point of convergence. Importantly, morphine limits the ability of neurons to recover from
sublethal damage.

Materials and Methods
Ethics statement
Experiments were conducted in accordance with procedures reviewed and approved by the
Virginia Commonwealth University Institutional Animal Care and Use Committee (Protocol
Number: AM10158).
Mixed glial cultures
Cells were cultured from the striatum, a region targeted by HIV where opioid receptor levels are
relatively high. Mixed glial cultures (astrocytes and microglia) from mouse striatum were
prepared as previously described [151, 153], with minor modifications. Striata from P0-P1 ICR
(CD-1) mice (Charles River Laboratories International, Inc., Wilmington, MA) were dissected,
minced and enzymatically dissociated with trypsin (2.5 mg/ml; Sigma-Aldrich, St. Louis, MO)
and deoxyribonuclease (DNase; 0.015 mg/ml; Sigma-Aldrich) in Dulbecco’s Modified Eagle’s
Medium (DMEM; Gibco, Grand Island, NY) for 30 min at 37°C. Tissue was resuspended in
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DMEM supplemented with 10% fetal bovine serum (FBS; Gibco), triturated and filtered through
100 and 40 μm nylon mesh pore filters respectively. Cells were plated and maintained in
supplemented DMEM containing 10% FBS.
Neuronal cultures
Mouse striatal neuron cultures were prepared as previously described [151, 153]. Briefly, striata
from E15-E16 ICR mice were dissected, minced and enzymatically dissociated with trypsin (2.5
mg/ml) and DNase (0.015 mg/ml) in neurobasal medium (Gibco) for 30 min at 37°C. Tissue was
resuspended in neurobasal medium supplemented with B-27 additives (Gibco), L-glutamine (0.5
mM; Gibco) and glutamate (25 µM; Sigma-Aldrich), triturated and filtered twice through 70 µm
nylon mesh pore filters. Neurons were plated and maintained in supplemented neurobasal
medium. Culture purity was determined by immunocytochemistry using anti-MAP-2 antibody
(Abcam, Cambridge, MA; ab32454) and found to be > 80% neurons.
Neuron-mixed glial co-cultures
All cultures were prepared in 24 well plates pre-coated with poly-L-lysine (0.5 mg/ml; SigmaAldrich). Neurons were plated alone in 12 wells (neuron cultures); in the remaining 12 wells we
established neuron-glia co-cultures as previously described [153]. Briefly, two deep midline
grooves were made into the culture surface to restrict the movement of glial cells between sides.
Glial cells (2×105 cells/well) were plated on one side of the grooves; when they became
confluent (10 d), neurons (0.25×105 cells/well) were plated onto the entire culture surface. In
these wells, all neurons are exposed to glial conditioned medium, but neurons on one side of the
grooves contact the glial bedlayer, while neurons on the other side grow in isolation on the
culture surface. It is difficult to visualize all neurite extensions when neurons are in contact with
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the glial bedlayer. Thus, the co-culture studies used neurons that did not have direct contact with
glia. All cultures were maintained in supplemented neurobasal medium; neurons were allowed to
mature for 5-7 d prior to treatment.
Supernatant from HIV-infected cells
U937 cells (ATCC, Manassas, VA), a leukemic monocyte cell line originally derived from a
histiocytic lymphoma, were plated at 0.5 × 105 cells/ml in RPMI-1640 media (Gibco)
supplemented with 10% FBS, and activated/differentiated with interleukin-2 (IL-2, 100 ng/ml;
Sigma-Aldrich), phytohaemagglutinin (PHA, 5 µg/ml; Sigma-Aldrich), and phorbol 12-myristate
13-acetate (PMA, 100 ng/ml; Sigma-Aldrich), for 48 h. Activated/differentiated cells were
treated with Polybrene (2 μg/ml; Sigma-Aldrich) for 30 min at 37°C, resuspended in fresh
medium and exposed to HIV-1SF162 (p24 = 50-100 pg/ml; from Dr. Jay Levy [215], through the
NIH AIDS Research and Reference Reagent Program, Germantown, MD). After 7 d,
supernatants were collected by filtering through a 0.20 μm filter. HIV infection was confirmed
by quantification of p24 levels (HIV-1 p24 Antigen Capture Assay; Advanced Bioscience
Laboratories, Rockville, MD) in culture supernatants; a 4-6 fold increase in p24 antigen levels
was typical over 7 d. Supernatants from uninfected/untreated U937 cells (Controlsup) were used
as a control. Cell culture supernatants were aliquoted and stored at -80°C.
Treatments
Morphine is the major metabolite of heroin in the CNS [216]; it preferentially targets µ-opioid
receptors (MORs). Since opiates by themselves can affect HIV-1 infection and replication [217],
it was important to assess the effects of opiate interactions using cell-free supernatants. HIV+sup
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or Controlsup was added to neuronal cultures in the presence or absence of morphine sulfate (500
nM; Sigma-Aldrich) ± naloxone (1.5 µM; Sigma-Aldrich), a general opioid receptor antagonist.
MTT assay
At specific times after treatment, cells were rinsed and incubated with 1.2 mM 3-(4,5Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Molecular Probes, Grand Island,
NY) in fresh, pre-warmed media at 37°C for 4 h. The medium was gently aspirated, and
formazan crystals, the product of reduction of MTT by mitochondrial dehydrogenase in live
cells, were dissolved in 100 µl of dimethyl sulfoxide (DMSO; Sigma-Aldrich) at 37°C for 10
min. The amount of formazan was measured by absorbance at 540 nm using a PHERAstar
microplate reader (BMG LABTECH Inc., Cary, NC).
TUNEL assay
At specific intervals after treatments, cells were fixed overnight at 2-8°C in 4%
paraformaldehyde (Sigma-Aldrich), permeabilized at room temperature in 0.1% Triton-X 100
(Molecular Probes) and 0.1% BSA (Invitrogen, Grand Island, NY) for 15 min, and blocked in
0.1% BSA and 1% horse serum for 30 min. Fixed cells were stained for Hoechst 33342 (SigmaAldrich) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL; Roche
Applied Sciences, Mannheim, Germany). Cells were visualized and digital images were acquired
using an Axio Observer Z.1 microscope and Zen 2010 software (Zeiss Inc., Thornwood, NY).
Neuronal apoptosis was assessed by manually counting the percentage of TUNEL(+) cells.
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Assessment of neuronal viability
In each culture well, at least 50 healthy neurons were initially selected in 6-8 non-overlapping
fields. After treatment, repeated images of pre-selected cells were captured at 1 h intervals, using
a microscope with a computer-regulated stage (Axio Vision 4.6; Carl Zeiss Inc.) under controlled
environmental conditions (37°C, 95% humidity and 5% CO2) [151, 153]. At the end of each
experiment, pre-selected neurons were assessed for viability at 6 h intervals in the digital images.
Cell death was confirmed using rigorous morphological criteria including abnormal shrinking of
the cell body and eventual cell body fragmentation, nuclear destruction, loss of phase-brightness,
and excessive neurite loss [151, 153, 218]. In some experiments, live and dead cells were
confirmed at the end of the experiment by staining respectively with calcein-AM and ethidium
homodimer-1 (LIVE/DEAD Viability/Cytotoxicity Kit; Molecular Probes, Grand Island, NY).
Findings were reported as the average percentage of neuron survival, with respect to pretreatment neuron count ± standard error of the mean (SEM), and analyzed using a repeated
measure analysis of variance (ANOVA) and Duncan’s post hoc test using Statistica 8.0 (StatSoft,
Tulsa, OK).
Assessment of neurite length
At specific intervals after treatments, cells were fixed, permeabilized, blocked, and subsequently
stained for TUNEL and MAP-2 (Abcam; ab32454); cells were visualized and digital images
were acquired. In digital images, neuritic arborization was quantified only for live [TUNEL(-)]
neurons, using modified Sholl analysis. A ‘Sholl score’ was measured by counting the number of
intersections of MAP-2-positive neurites with equidistant concentric circles of increasing radius,
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centered on the cell body [219]. The Sholl score was converted into neurite length in µm via
micrometer calibration at the same magnification.
Assessment of neurite growth/regrowth after treatment removal
Prior to treatment, at least 15 healthy neurons were selected in 7-8 non-overlapping fields per
well. Repeated images of pre-selected cells were captured at 1 h intervals after treatment onset.
After 24 h, cells were gently rinsed with pre-warmed medium and returned either to a ‘control ±
opiate environment’, which had Controlsup, or to a ‘HIV ± opiate environment’ which had
HIV+sup (Table 1). We then continued to capture images of the same neurons at 1 h intervals for
an additional 48 h (total 72 h). Thus, there were a total of 9 groups with varying exposure times
to HIV+sup or Controlsup, in the presence or absence of morphine ± naloxone; these are outlined in
Table 1.
Neurons that remained alive until the experiment end (72 h) were assessed for neuritic
arborization in images taken at 0 h, 24 h, and 72 h using Sholl analysis. The findings were
reported as average Sholl scores at each time, normalized to pre-treatment (0 h) scores ± SEM.
Data were analyzed using a repeated measure ANOVA and Duncan’s post hoc test using
Statistica 8.0 (StatSoft).
ELISA
Conditioned medium from mixed glial cultures were collected on the schedule described in
Table 1 and assessed for brain-derived neurotrophic factor (BDNF), glial cell-derived
neurotrophic factor (GDNF), interleukin 6 (IL-6) and tumor necrosis factor α (TNFα) by ELISA
according to the manufacturer’s instructions (BDNF and GDNF ELISAs: Abcam; IL-6 and
TNFα ELISAs: R&D Systems, Minneapolis, MN). 3,3’,5,5’-tetramethylbenzidine (TMB)
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substrate was added for color development and plates were read at 450 nm using a PHERAstar
microplate reader immediately after terminating the reaction. Protein levels were determined
based on a standard curve.
Immunoblotting
Whole cell extracts were prepared using radioimmunoprecipitation assay (RIPA) buffer (SigmaAldrich) with protease and phosphatase inhibitors (cOmplete - protease inhibitor cocktail tablets,
and PhosSTOP - phosphatase inhibitor cocktail tablets; Roche), and total protein concentrations
were determined by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Rockford, IL).
Cell lysates containing equal amounts of total protein (~5-10 μg) were heated at 100º C for 5
minutes in laemmli buffer (Sigma-Aldrich), electrophoretically separated on a 10% SDSpolyacrylamide gels (Criterion Precast Gel; Bio-Rad, Hercules, CA), and transferred onto
polyvinylidene difluoride (PVDF) membranes (Immun-Blot; Bio-Rad). Membranes were
incubated with primary antibodies for phospho-GSK3β-Ser9 (p-GSK3β-S9; Cell Signaling
Technology, Danvers, MA; 5558), GSK3β (t-GSK3β; Cell Signaling Technology; 9832) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Abcam; ab8245). Appropriate horseradish
peroxidase-conjugated secondary antibodies (SouthernBiotech, Birmingham, AL) were used.
Membranes were detected using SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Fisher Scientific), and visualized using a Kodak Image Station 440CF.
Statistical Analyses
All data were expressed as average ± SEM. Unless otherwise indicated, data were analyzed
statistically using a one-way ANOVA followed by Duncan’s post hoc test using Statistica 8.0
(StatSoft); an α level of p < 0.05 was considered significant.
21

Results
Dose dependent neuron death and interactions with morphine
To determine the HIV+sup concentration for subsequent experiments we assessed concentrationdependent toxicity in the presence or absence of 500 nM morphine, a titer chosen to maximally
stimulate neuronal and glial MORs in vitro, and to result in dynamic Ca2+ changes and secretion
of multiple cytokines and chemokines [145-147, 149, 151, 153, 220, 221]. HIV+sup at p24 ≥ 25
pg/ml and above showed significant toxicity even in the absence of morphine in an MTT assay.
As expected, there was a concentration-dependent decrease in MTT reduction, indicating lower
mitochondrial activity at higher HIV+sup levels. At p24 concentrations ≤ 10 pg/ml, HIV+sup did
not affect the MTT assay unless cells were co-exposed to morphine, indicating a significant
synergistic effect (Fig. 2.1). At p24 concentrations ≥ 25 pg/ml, there were no significant
interactions of HIV+sup with morphine. The MTT assay is a measure of the activity of NADH and
NADPH-dependent cellular oxidoreductase enzymes [222-224]. Although it is frequently used as
an indicator of cell survival/toxicity or proliferation, it is only an indirect measure. Therefore,
neuron survival was directly assayed using time-lapse imaging (Fig. 2.2). Like the MTT assay,
time-lapse image analysis showed a p24 concentration-dependent decrease in neuron survival
over a 48 h period (Fig. 2.2B). In contrast to the MTT assay, time-lapse image analysis also
revealed interactive effects between HIV+sup and morphine on cell death at p24 concentrations of
10 and 25 pg/ml. As a p24 concentration of 25 pg/ml caused significant death/toxicity and also
showed interactive effects with morphine, this titer was used in all further experiments.
Importantly, 25 pg/ml falls within the range of p24 levels detected in the CSF of HAND patients
on antiretroviral therapy (p24 = 43.2 ± 16.8 pg/ml) [225].
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Toxic effects of HIV ± morphine in neuron cultures
Neuronal apoptosis was assessed using TUNEL staining (Fig. 2.3); all HIV+sup treatment groups
showed significantly enhanced neuronal apoptosis at all assessed time-points (Fig. 3B; Neuron
panel). At all time-points, except 12 h, morphine significantly enhanced HIV+sup-mediated
neuronal apoptosis and the interactive effects of morphine were blocked by naloxone. TUNEL
staining is specific for death involving apoptotic pathways, and may not detect all dying neurons.
Additionally, TUNEL does not distinguish and permit the exclusion of cells that were dead at the
start of the treatment. Time-lapse imaging was used to more exactly follow cell survival/death
(Fig. 2.4). Over the period of 72 h, HIV+sup ± morphine treatments significantly reduced neuronal
survival in cultures without glia (Fig. 4; Neuron panel). Morphine significantly enhanced
neuronal death mediated by HIV+sup, and interactive effects of morphine were blocked by
naloxone.
Sublethal synaptic losses and neuritic pruning are thought to be a major substrate of
neurocognitive disorders [87-91]. Therefore, effects of HIV+sup ± morphine treatment on neuritic
arborization were assessed using MAP-2-immunostaining followed by modified Sholl analysis
(Fig. 2.5); only those neurons determined to be alive by TUNEL assay were used in the analysis.
At all assessed time-points, HIV+sup ± morphine treatment groups showed significantly reduced
neurite length (Fig. 2.5B; Neuron panel). Morphine did not show a significant interaction with
HIV+sup at any time.
Role of glia in HIV ± morphine-mediated neurotoxicity
HIV does not infect mature neurons; instead, virotoxins can cause indirect neuron damage via
inducing an inflammatory response in activated and/or infected glia [22, 65, 88, 211, 212]. To
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determine the role of glia in HIV+sup ± morphine-mediated neurotoxicity, treatments were carried
out either in the presence or absence of glia. The presence of glia significantly increased the
proportion of HIV+sup ± morphine-induced TUNEL(+) neurons (Fig. 2.3B; compare panels). At
the earliest time point examined (12 h), HIV+sup and morphine displayed a significant interaction;
however this only occurred in the presence of glia. Thus, glia appeared to accelerate the HIV+supmorphine interaction. At all time points except 72 h, the interactive effects of morphine were
significantly attenuated by naloxone. Chronic exposure to naloxone is occasionally ineffective,
even when acute blockade reverses morphine effects [226]. This may be due to blocking the
cellular effects of the multiple opioids normally released by glia [227, 228]. The presence of glia
significantly enhanced HIV+sup ± morphine-mediated neuron death over the entire 72 h
experimental period (Fig. 2.4; compare panels).
In the subpopulation of neurons that survived, HIV+sup induced significant neurite pruning or
growth arrest. The presence of glia did not significantly affect HIV+sup-induced neurite pruning,
even when neurons were co-exposed to morphine. In fact, in the presence of glia, Controlsuptreated groups had significantly longer neurites (Fig. 2.5B; compare panels).
Reversibility of HIV ± morphine-mediated neurite damage
Neurons appear to recover from certain types of sublethal damage caused by HIV-related insults
[87, 88, 90]. Therefore, the reversibility of HIV- and morphine-mediated neurite damage was
tested. HIV+sup ± morphine treatments caused significant neurite growth arrest over the period of
24 h in cultures without glia (Fig. 2.6B; Neuron panel). With continuous exposure to HIV+sup ±
morphine for 72 h, neurite length remained significantly reduced. When HIV+sup was removed at
24 h, neurites resumed their growth. Interestingly, sustained exposure to morphine by itself was
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sufficient to reduce and/or delay neurite recovery/outgrowth despite the removal of HIV+sup. This
effect of morphine was blocked by naloxone.
Since glia support neurite outgrowth and synapse remodeling through multiple mechanisms
[229-232] we tested whether glia play a role in the reversibility of HIV- and morphine-mediated
neurite pruning/growth arrest. As in the neuron-only cultures, HIV+sup ± morphine treatments
caused significant neurite growth arrest over 24 h when glia were present (Fig. 2.6B; Neuron-glia
panel). In the presence of glia, neurite outgrowth was significantly faster after removal of
HIV+sup than it was in neuron-only cultures (Fig. 2.6B; compare panels).
HIV- and morphine-mediated effects on secretion of growth factors and cytokines by glia
Our results show that glial effects on neuron injury and recovery are dependent on the context of
HIV and morphine. Glia enhanced HIV-driven neuronal death (Fig. 2.3B and 2.4), but
accelerated neurite recovery after removal of HIV (Fig. 2.6B). To determine how glia might
direct these outcomes, we examined whether HIV and morphine affect glial production of
secreted factors known to influence neuronal survival and outgrowth. ELISA was used to assay
levels of the neurotrophic factors (BDNF and GDNF), as well as cytokines (IL-6 and TNFα) that
indicate glial inflammatory activation (Fig. 2.7); they showed multiple response patterns. BDNF
levels were significantly reduced by HIV+sup ± morphine treatments. BDNF recovered to control
levels after removal of HIV+sup, even though morphine remained present. GDNF levels were
unaffected by any treatment. IL-6 levels were increased by HIV+sup or morphine treatment alone,
and in addition, morphine significantly augmented the effect of HIV+sup. Although IL-6 levels
returned to control after removal of HIV+sup, the elevated levels were maintained in the continued
presence of morphine. TNFα release was significantly increased by HIV+sup alone, but not by
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morphine alone, although morphine co-treatment augmented the effect of HIV+sup. TNFα levels
returned to control after removal of HIV+sup, even in the continuous presence of morphine. Thus,
among the secreted factors whose levels were influenced by HIV and morphine, BDNF, TNFα
and IL-6 responded to HIV+sup alone, while only IL-6 was affected by morphine itself. Both
TNFα and IL-6 showed HIV-morphine interactive effects. Only IL-6 continued to respond to
morphine exposure after HIV removal.
GSK3β as a point of convergence for HIV and morphine
Previous studies have shown that HIV-1 induces neurotoxic effects by enhanced activation of
GSK3β [174, 184-188], and that GSK3β is also linked to neuropathology seen with opiateabusing patients [141, 142]. We therefore tested whether GSK3β might be a site of HIV and
morphine interactions. Neurons grown in isolation were lysed at 24 h after treatments with
HIV+sup ± morphine and immunoblotted for phospho-GSK3β-Ser9 (p-GSK3β-S9; an inactive
form of GSK3β [165, 173, 175, 233]), GSK3β (total GSK3β; t-GSK3β) and GAPDH (Fig. 2.8).
HIV+sup and morphine by themselves induced significant reduction in p-GSK3β-S9 with respect
to t- GSK3β. Morphine co-treatment significantly augmented HIV+sup-mediated effects. All of
the effects of morphine were blocked by naloxone.

Discussion
Our studies conclusively show that opiates can directly exacerbate the deleterious effects of
HIV-1 on neurons in an infective model in vitro, although past studies have demonstrated that
morphine interacts with the HIV-1 proteins Tat [149, 153] and gp120 [151]. The present studies
also confirm and extend prior findings of glial involvement in interactions between opiates and
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HIV proteins, demonstrating that combined morphine and HIV-1SF162 neurotoxicity can be
amplified in the presence of glia. Lastly, we found that continuous morphine exposure
significantly restricted the ability of neurons to recover from exposure to HIV+sup. This suggests
that HIV-opiate co-exposure may trigger maladaptive cellular responses that persist in the
presence of opiates alone, even after HIV infection is mitigated. Importantly, this situation is
relevant to opiate-exposed patients whose HIV infection is controlled with cART.
Experimental models for HIV ± opiate-mediated neurotoxicity
Since HIV is a human-specific disease, models in other species have deficiencies as well as
strengths. For example, non-human primates have been an invaluable model to assess interactive
effects of the HIV-like simian immunodeficiency virus (SIV) and opiates [234, 235]. However,
limited availability and the lack of established simian culture models make mechanistic studies
difficult. There are rodent in vivo models that closely mimic viral infection, including an HIV-1
transgenic rat that expresses a majority of HIV-1 proteins without viral replication [236], and
“humanized” SCID mice in which establishment of a human immune system in mice permits
HIV infection [237]. However, in both cases the peripheral and central target cells are those of
the rodent host. Our past in vivo studies have used a Tat transgenic mouse in which Tat
production is largely restricted to the CNS [145, 148], and we have also examined effects of
HIV-1 proteins on murine cells in vitro [149, 151-153, 218, 238]. In general, the findings in
culture have paralleled outcomes in vivo; all have closely modeled key aspects of
neurodegeneration and inflammatory biomarker production seen clinically in the CNS. We are
specifically interested in effects on striatal neurons, since the striatum is a major target of HIV-1,
and since levels of opioid receptors in the striatum are relatively high [149, 239, 240]. Although
primary human cells may be preferable as an in vitro model, we have used murine targets since
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human neurons/glia from specific brain regions are not consistently available, and outcomes
frequently show regional specificity [241, 242]. Additionally, murine cultures (a) eliminate
human genetic variability in terms of MOR [243], CCR5 [244, 245], and other factors that
influence infective and neurodegenerative processes; and, (b) are free from any confounding
effects of morphine on HIV replication in human microglia [217]. Still, the issue of species
mixing must be considered when interpreting results in this model.
Neurotoxicity induced by HIV ± morphine
The extent to which opiates contribute to the progression of HAND in the era of cART remains
controversial, although some large clinical studies now support moderate interactive effects [160,
161]. Opiate drugs of abuse have been shown to enhance particular damaging effects of HIV-1
proteins in vitro [149-153]. However, the CNS of HIV-1-infected patients is exposed to a great
many other cellular and viral factors released from infected and/or activated cells. Current
studies therefore used supernatant from HIV-infected cells to more fully represent the variety of
those toxic and protective elements. HIV+sup caused neuronal death in a concentration-dependent
manner over a range of p24 levels (10-500 pg/ml, Fig. 2.1 and 2.2), but significant morphine
interactions were observed only at lower p24 levels (10 and 25 pg/ml). Very high levels of
neuronal death at p24 ≥ 100 pg/ml may have masked interactive effects. If, as our data suggest,
HIV-1-opiate interactions are partly governed by the level of infection, HIV-1 patients receiving
cART may be especially vulnerable to opiate interactions since cART has greatly reduced the
viral load [105, 111, 112]. The sensitivity of HIV-opiate interactions to levels of infection may
also explain some controversy concerning the role of opiates in severity of HAND.
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Since synaptic losses and neuritic pruning/degeneration are thought to be the principal substrate
underlying HAND [87-91], we also examined length of neurites in cells that survived treatments.
Our results show that HIV+sup reduced the length of neurites, but unlike the cell death results,
there were no significant morphine interactions (Fig. 2.5). Since HIV+sup and morphine can
induce multiple pathways, it is easily envisioned that interactions may differ between outcome
measures. In some instances, cumulative reductions in synapses and dendritic simplification may
culminate in cell death. Alternatively, neurite pruning may result in significant loss of cellular
functions, but neurons may remain alive [238, 246]. Control treated groups actually showed an
increase in the length of neurites over the same timeframe. This suggests that neurite length
changes mainly reflected neurite growth arrest/inhibition. Results from repeated neurite length
assessments of individual cells (Fig. 2.6) support this hypothesis. These conclusions are in
conflict with some previous studies [152, 238, 247], where reduction in neurite length was
mainly attributed to pruning of existing neurites. Disparate findings may reflect different types of
neurons, their age and relative maturity, the response of neurons to individual viral proteins
versus the multiple stimuli in HIV+sup, and the selection criteria for neurons; we specifically
evaluated sub-lethal neurite length changes by assessing only [TUNEL(-)] cells instead of the
entire population.
Although many experimental and epidemiological studies have indicated a link between opiate
drug exposure and HAND severity, the mechanisms underlying interactions between HIV-1 and
opiates remain largely obscure. HIV-1 is known to induce neurotoxic effects through abnormal
activation of GSK3β, and the GSK3β inhibitors, lithium (Li) and valproic acid (VPA),
ameliorate HIV-1-mediated neurotoxicity [174, 184-188]. GSK3β signaling is also implicated in
neuropathologic responses to opiates. For example, the accelerated deposition of
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hyperphosphorylated tau that occurs in the CNS of young opiate abusers [141, 142] may be
related to elevated GSK3β expression seen in opiate abusers [141] since GSK3β is a principal tau
kinase [195-197]. GSK3β plays a crucial role in regulating the levels and function of various
structural and signaling proteins in neurons including tau, MAP2, β-catenin, activator protein 1
(AP-1), cyclic AMP response element binding protein (CREB), heat shock factor-1 (HSF-1), and
among others, all of which regulate neuronal plasticity, gene expression and survival [165, 166,
175]. GSK3β is thus well-positioned to be a potential convergence point for interactions between
HIV-1 and opiates that regulate neuronal damage. Our results show that morphine co-exposure
significantly augments HIV+sup-mediated GSK3β-activation (Fig. 2.8), supporting this
hypothesis.
Role of glia in HIV ± morphine-mediated neurotoxicity
Opiates exacerbate the release of numerous factors with neurotoxic potential from glia exposed
to HIV [125, 147, 155], and alone or in concert with HIV can disrupt certain neuron-supportive
functions of glia, including glutamate buffering, free radical scavenging, phagocytosis and
release of neurotrophic factors [153, 155, 248, 249]. It is easily appreciated that glia might play a
crucial role in HIV-opiate interactions; in our previous studies glia were actually required for
interactive neurotoxicity between morphine and HIV-1 Tat [153]. In the present study, morphine
significantly enhanced HIV+sup-mediated striatal neuron death even in the absence of glia. One
obvious interpretation is that morphine interacts with factors in addition to HIV-1 Tat in the
HIV+sup. Even among R5 strains, unique gp120 sequences may result in a different degree of
interaction between opiates and HIV [151]. While glia are clearly important determinants of
neurotoxic HIV-opiate interactions, some interactions, perhaps those involving factors other than
Tat, seem to occur directly upon neurons.
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Glia also modified neurite recovery, enhancing outgrowth when HIV was removed. The effect of
glia on neurons is never entirely positive or negative but instead reflects the net input of various
effectors that either promote or damage neurite/neuron structure and function [229-232]. In this
context, our finding that glial production of BDNF is suppressed by HIV+sup but then rebounds to
control levels after removal of HIV+sup shows a return towards a more trophic glial function. The
normalization of proinflammatory cytokines TNFα and IL-6 after HIV removal indicates a
similar trend, although note that continued exposure to morphine partly abrogates the effect of
removing HIV (Fig. 2.7).
Overall, our results show that cellular and viral products released from HIV-1SF162-infected
leukemic monocytes have significant negative consequences on striatal neurons. Coincident
exposure to morphine worsens neuronal outcomes in a concentration- and time-dependent
manner. This is especially true when glia are present, although the net effects of glial exposure
depend upon the local levels of virus and opiates. At lower viral titers, HIV+sup has sublethal
effects on growth of neurite arbors, indicating that neurons may undergo functional changes long
before they die. This may be quite relevant to the situation in HIV-infected patients where
dendritic/synaptic plasticity, not neuron death, is the presumed substrate of HAND. Diminished
infection levels in the CNS are probably critical in reversing HIV-driven neurite damage,
although our results caution that chronic exposure to opiates may inflict damage even in the
absence of HIV.
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Tables
Treatment Groups

Treatment from 0 to 24 h

Treatment from 24 to 72 h

72h (C)

Control

Control

72h (C + M)

Control + Mor

Control + Mor

72h (C + M + N)

Control + Mor + Nal

Control + Mor + Nal

72h (H)

HIV

HIV

72h (H + M)

HIV + Mor

HIV + Mor

72h (H + M + N)

HIV + Mor + Nal

HIV + Mor + Nal

24h (H) then 48h (C)

HIV

Control

24h (H + M) them 48h (C + M)

HIV + Mor

Control + Mor

24h (H + M + N) then 48h (C + M + N)

HIV + Mor + Nal

Control + Mor + Nal

Table 2.1: Treatment paradigm for neurite growth/regrowth assessments. Control =
Controlsup; HIV = HIV+sup (p24 = 25 pg/ml); Mor = morphine sulfate (500 nM); Nal = naloxone
(1.5 μM).
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Figures

Figure 2.1: Concentration-dependent change in MTT reduction. Cell toxicity/proliferation
was analyzed in neuron cultures at 48 h after treatment using an MTT assay. The findings were
reported as percent of control absorbance at 540 nm (A540) ± SEM. Significance was analyzed
using a one-way ANOVA and Duncan’s post hoc test, from n = 3 separate experiments. All
treatment groups, except morphine alone [Control + Mor] and p24 = 10 pg/ml of HIV+sup
[HIV(10)], showed significantly decreased absorbance at 540 nm (*p < 0.05 vs. Control), likely
reflecting neurotoxicity. HIV+sup caused a concentration-dependent reduction in A540 ($p < 0.05).
Morphine did not show a significant interaction with HIV+sup at any p24 level. Control =
Controlsup; HIV = HIV+sup (concentration of p24 in pg/ml is specified in parentheses); Mor =
morphine sulfate (500 nM).
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Figure 2.2: Concentration-dependent neuronal death in cultures treated with HIV+sup ±
morphine. Individual striatal neurons were selected prior to treatment and repeatedly imaged
for 48 h after treatment. (A) Digital images of the same cells/fields, at 0 h, 24 h and 48 h after
treatment (white arrowheads indicate cells that have died over the previous 24 h period). Live
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and dead cells were confirmed at the end of the experiment by staining respectively with calceinAM (green) and ethidium homodimer-1 (red); scale bar = 40 µm. (B) Cells were assessed for
viability at 6 h intervals in digital images. Findings were reported as the average neuronal
survival as a percent of pre-treatment neuron count ± SEM. Significance was analyzed by
repeated measures ANOVA and Duncan’s post hoc test, from n = 3 separate experiments (at
least 150 neurons per treatment group). Over the period of 48 h, all treatment groups except
morphine alone [Control + Mor] and p24 = 10 pg/ml of HIV+sup alone [HIV(10)], showed
significantly reduced neuronal survival (*p < 0.05 vs. Control). Neuronal survival declined in a
concentration dependent manner with HIV+sup treatment ($p < 0.05). Morphine showed
significant interaction with HIV+sup, but only at lower levels of exposure (p24 = 10 and 25 pg/ml)
(#p < 0.05 vs. HIV+sup alone at corresponding titer). Control = Controlsup; HIV = HIV+sup
(concentration of p24 in pg/ml is specified in parentheses); Mor = morphine sulfate (500 nM).
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Figure 2.3: Neuronal apoptosis induced by HIV+sup ± morphine. Cells were fixed at specific
intervals after treatment and labeled for Hoechst 33342 (blue) and TUNEL (red). (A) Digital
images of neuronal cultures at 72 h after treatment; scale bar = 40 µm. (B) Apoptosis was
assessed by manually counting the percentage of TUNEL(+) cells. Findings were reported as the
average percentage of TUNEL(+) cells ± SEM. Significance was analyzed by one-way ANOVA
and Duncan’s post hoc test, from n = 4 separate experiments. At all assessed time points, in both
culture systems, all groups exposed to HIV+sup showed significantly enhanced neuronal apoptosis
(*p < 0.05 vs. respective C group). In all cases, except at 12 h in cultures with neurons alone,
morphine significantly augmented HIV+sup-mediated neuronal apoptosis (#p < 0.05 vs. respective
H group). In all cases, except for 72 h in neuron-glia cultures, the interactive effects of morphine
were significantly attenuated by naloxone. In most cases, the presence of glia significantly
enhanced HIV+sup ± morphine-mediated neuron apoptosis ($p < 0.05 vs. corresponding treatment
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in neuron cultures; compare panels). C = Controlsup; H = HIV+sup (p24 = 25 pg/ml); M =
morphine sulfate (500 nM); N = naloxone (1.5 µM).
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Figure 2.4: HIV+sup ± morphine-mediated neuronal death. Neurons were repeatedly imaged
for 72 h after treatment. Cells were assessed for viability at 6 h intervals in digital images. The
findings were reported as the average percentage of neuron survival with respect to pre-treatment
neuron count ± SEM. Significance was analyzed by repeated measures ANOVA and Duncan’s
post hoc test, from n = 6 separate experiments. Over the period of 72 h, in both culture systems,
all groups exposed to HIV+sup showed significantly reduced neuronal survival (*p < 0.05 vs. C).
Morphine significantly enhanced HIV+sup-mediated neuronal death (#p < 0.05 vs. H), and the
interactive effects of morphine were blocked by naloxone. In the presence of glia, HIV+sup ±
morphine-mediated neuronal death was significantly enhanced ($p < 0.05 vs. corresponding
treatment in neuronal cultures; compare panels). C = Controlsup; H = HIV+sup (p24 = 25 pg/ml);
M = morphine sulfate (500 nM); N = naloxone (1.5 µM).
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Figure 2.5: HIV+sup ± morphine-mediated neurite damage. Cells were fixed at specific
intervals after treatment and labeled for MAP-2 (green) and TUNEL (red). (A) Digital images of
neuronal cultures at 72 h after treatment; scale bar = 40 µm. (B) The ‘Sholl score’ was assessed
only for TUNEL(-) neurons in the digital images and converted into neurite length in µm via a
micrometer-scale calibration. The findings were reported as average total neurite length per
neuron (µm) ± SEM. Significance was analyzed by one-way ANOVA and Duncan’s post hoc
test from n = 4 separate experiments. At all time-points and in both culture systems, all groups
exposed to HIV+sup showed significantly reduced neurite length (*p < 0.05 vs. C). Morphine did
not show a significant interaction with HIV+sup treatment. The presence of glia did not have a
significant effect on HIV+sup ± morphine-mediated neurite damage, but in the presence of glia,
Controlsup-treated groups showed significantly longer neurite length ($p < 0.05 vs. corresponding
treatment in neuron cultures; compare panels). C = Controlsup; H = HIV+sup (p24 = 25 pg/ml); M
= morphine sulfate (500 nM); N = naloxone (1.5 µM).
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Figure 2.6: Reversibility of HIV+sup ± morphine-mediated neurite damage. Images of preselected neurons were captured for 24 h after initial treatments, and for an additional 48 h after
treatments were changed as described in Table 1. (A) Digital images of neuronal cultures after
specified time and treatments (white arrowheads indicate area of neurite outgrowth since
previous image); scale bar = 40 µm. (B) Neurons that remained alive until the experiment end
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(72 h) were assessed for their arborization in images taken at 0, 24 and 72 h, using Sholl
analysis. The findings were reported as average Sholl scores at each time, normalized to pretreatment (0 h) scores ± SEM. Significance was analyzed by repeated measures ANOVA and
Duncan’s post hoc test, from n = 45-60 neurons per treatment group (sampled from 3 separate
experiments; at least 15 neurons per group per experiment). Over the period of 24 h, and in both
culture systems, HIV+sup ± morphine treatments induced neurite growth arrest; in neuron-glia cocultures, HIV+sup + morphine treatment appeared to cause neurite pruning (*p < 0.05 vs. 0 h, for
corresponding treatment). After removing HIV+sup at 24 h, neurite growth arrest was reversible
($p < 0.05 vs. 24 h, for corresponding treatment); however, if HIV+sup ± morphine treatments
were continued for 72 h, then neurite growth arrest was persisted. If morphine treatment
continued after the removal of HIV+sup, neurite outgrowth was significantly reduced/delayed
compared to neurons returned to Controlsup (#p < 0.05 vs. ‘24 h (H) then 48 h (C)’). This effect of
morphine was blocked by naloxone. In the presence of glia, neurite outgrowth after removal of
HIV+sup was significantly enhanced, even in the continued presence of morphine (§p < 0.05 vs.
corresponding treatment and time point in neuronal cultures; compare panels). C = Controlsup; H
= HIV+sup (p24 = 25 pg/ml); M = morphine sulfate (500 nM); N = naloxone (1.5 µM).

41

Figure 2.7: HIV+sup ± morphine-mediated effects on secretion of growth factors and
cytokines by glia. After specified times and treatments, conditioned medium from mixed glial
cultures was collected and assessed for levels of BDNF, GDNF, IL-6 and TNFα by ELISA;
Growth factor / cytokine levels were determined based on a standard curve. The findings were
reported as average concentrations (pg/ml) ± SEM. Significance was analyzed using a one-way
ANOVA and Duncan’s post hoc test, from n = 3 separate experiments. BDNF: HIV+sup ±
morphine treatments significantly reduced levels of BDNF (*p < 0.05 vs. ‘72 h (C)’); after
removal of HIV+sup, BDNF returned to control levels ($p < 0.05). GDNF: HIV+sup ± morphine
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treatments did not have significant effects on GDNF levels. IL-6: HIV+sup treatment significantly
enhanced levels of IL-6; morphine treatment alone also significantly elevated IL-6 levels (*p <
0.05 vs. ‘72 h (C)’), and morphine co-treatment significantly augmented HIV+sup-mediated
effects (#p < 0.05). After removal of HIV+sup, IL-6 returned to control levels ($p < 0.05); in the
continuous presence of morphine, IL-6 remained at a significantly higher level than control (*p <
0.05) and [24h (H) then 48h (C)]-treatment group (#p < 0.05). TNFα: HIV+sup treatment
significantly enhanced levels of TNFα (*p < 0.05 vs. ‘72 h (C)’); morphine co-treatment
significantly enhanced the HIV+sup-mediated effect (#p < 0.05). After removal of HIV+sup, TNFα
levels returned to control values ($p < 0.05). C = Controlsup; H = HIV+sup (p24 = 25 pg/ml); M =
morphine sulfate (500 nM).
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Figure 2.8: HIV+sup ± morphine-mediated GSK3β activation. Cells were lysed and
immunoblotted for p-GSKβ-S9 (an inactive form of GSKβ), t- GSKβ (total GSKβ) and GAPDH
in neuronal cultures at 24 h after treatment. Findings were reported as a percent of control values
of p-GSKβ-S9 levels normalized with t-GSKβ (p-GSKβ-S9/t-GSKβ) ± SEM. Significance was
analyzed using a one-way ANOVA and Duncan’s post hoc test, from n = 3 separate experiments.
HIV+sup caused significant loss of p-GSKβ-S9 (*p < 0.05 vs. C). Treatment with morphine alone
also caused significant loss of p-GSKβ-S9, and morphine co-treatment significantly augmented
the HIV+sup-mediated effect (#p < 0.05). The effects of morphine were blocked by naloxone. C =
Controlsup; H = HIV+sup (p24 = 25 pg/ml); M = morphine sulfate (500 nM); N = naloxone (1.5
μM).
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CHAPTER 3
Comparison of HIV-1LAI and HIV-1SF162-Mediated Neurotoxicity and Interactions with
Opiates
(This chapter is in preparation to submit for publication)

Introduction
Nearly half of the human immunodeficiency virus-1 (HIV-1)-infected individuals suffer from a
wide range of neurological disorders, including motor disturbances, dementia and behavioral
changes, collectively known as HIV-1-associated neurocognitive disorders (HAND) [100-103].
HIV-1 enters the brain parenchyma soon after initial systemic infection [22-24, 250]. HIV-1
itself rarely infects neurons [22, 47, 49, 58]; instead, infected and/or activated glial cells produce
pro-inflammatory cytokines/chemokines and other cellular factors that, in conjunction with
secreted viral proteins, induce ‘bystander’ damage to neurons and other cells in the CNS [22, 6265, 251-253]. Though combination antiretroviral therapy (cART) has significantly improved the
health status of a large number of AIDS patients, it has not been proved equally effective for
HAND [88, 105-107, 111, 113, 254]. This high incidence of HAND despite cART may be due to
the longer survival of AIDS patients with milder neurocognitive disorders or result from limited
penetration of available anti-retroviral drugs across blood-brain barrier (BBB) [88, 112, 114], or
may be because of both.
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Nearly one third of HIV-infected patients have a history of drug abuse, commonly involving
opiates [125-127]. Because of sharing of contaminated needles and unsafe sexual activities, drug
abuse is a major risk factor for HIV-transmission. Since opiate drugs of abuse induce
immunosuppressive/immunomodulatory effects [132, 140, 255], they not only increase the risk
of HIV-infection but also exacerbate viral spread and disease progression. As opiate drugs of
abuse themselves induce neurotoxic effects, such as BBB breakdown, glial cell activation, and
neuronal injury [139, 140, 154, 158], it can be predicted that they may exacerbate HIV-1
pathogenesis in the CNS and the severity of HAND. Many previous studies have shown that
opiates interact with and exacerbate HIV-1-mediated neurotoxic effects [125, 145, 148-153,
256]. This mimics more severe neurocognitive deficits observed in opiate drug abusing HIV+
patients [160-162].
Although many studies have indicated the link between opiate drug abuse and HAND
progression, the extent to which opiates exacerbate neurocognitive deficits is still controversial
[257-260]. In current studies, we tried to determine whether morphine, the major active narcotic
metabolite of injected heroin [216], exacerbate HIV-1-mediated striatal neuron toxicity; we
tested our hypothesis using striatal cell cultures because the striatum is a principal target of HIV1 in the CNS and expresses high levels of opioid receptors [239, 240, 261, 262].
During initial stages of HIV-infection, R5-tropic strains predominate. However, during course
of infection, the virus goes under evolution, in later stages of disease X4-tropic strains are more
predominant. The co-receptor usage switch from CCR5 to CXCR4 is crucial in disease
progression to AIDS [263-267]. Some previous studies have shown that drugs of abuse interact
with virus or viral proteins in a strain/tropism-dependent manner [151, 268]. Our previous
studies have shown that certain neurotoxic effects induced by HIV-1SF162, a R5-tropic strain, are
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significantly enhanced by co-exposure to morphine [256]. The main aim of current work is to
determine whether HIV-1LAI, a X4-tropic strain induces similar neurotoxic effects and has
similar interactions with opiates, or whether induces differential effects in strain-dependent
manner.
Neurotoxic outcome measures were studied after treatments either with supernatant from HIV-1infected cells (HIV+sup) or with purified virions (HIVvirion), in the presence or absence of
morphine. Surprisingly, we found very little differences in X4 versus R5-tropic HIV+sup mediated
neurotoxicity and interactions with opiates. Interestingly, without intermediate effects of glia,
purified virions did not induce significant neurotoxic effects and also did not cause significant
interactions with morphine. Suggesting that HIV+sup mediated neurotoxic effects and interactions
with opiates are mainly due to cytotoxic/inflammatory milieu instead of virion itself.

Materials and Methods
Experiments were conducted in accordance with procedures reviewed and approved by the
Virginia Commonwealth University Institutional Animal Care and Use Committee.
Mixed glia cultures
Mouse striatal mixed glia (astrocytes and microglia) cultures were prepared as previously
described [151, 153, 256]. Briefly, striata from P0-P1 ICR (CD-1) mice (Charles River
Laboratories International, Inc., Wilmington, MA) were dissected, minced, and incubated with
trypsin (2.5 mg/ml; Sigma-Aldrich, St. Louis, MO) and deoxyribonuclease (DNase; 0.015
mg/ml; Sigma-Aldrich) in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Grand Island,
NY) for 30 min at 37°C. Tissue was resuspended in DMEM supplemented with 10% fetal bovine
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serum (FBS; Gibco), triturated, and filtered through 100 and 40 μm pore nylon mesh filters.
Cells were plated and maintained in DMEM supplemented with 10% FBS.
Neuron cultures
Neuron cultures from E15-E16 ICR (CD-1) mouse striatum were prepared as previously
described [151, 153, 256]. Striata were dissected, minced, and enzymatically dissociated with
trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in neurobasal medium (Gibco) for 30 min at
37°C. Tissue was resuspended in neurobasal medium supplemented with B-27 additives (Gibco),
L-glutamine (0.5 mM; Gibco) and glutamate (25 µM; Sigma-Aldrich), triturated and filtered
twice through 70 μm pore nylon mesh filters. Neurons were plated and maintained in
supplemented neurobasal medium.
Neuron-mixed glia co-cultures
All cultures were prepared in 24 well plates coated with poly-L-lysine lysine (0.5 mg/ml; SigmaAldrich). In half of the wells neurons were cultured alone (indicated as neuron or neuron-alone
cultures). In the remaining wells, we established neuron-mixed glia co-cultures (indicated as
neuron-glia cultures) as described previously [153, 256]. Two deep midline grooves were made
into the culture surface with a hot scalpel to inhibit the movement of glial cells between sides.
Glial cells (2×105 cells/well) were plated on one side of grooves by tilting the plate at a sufficient
angle. After glia on one side of the grooves were confluent (10 d), neurons (0.25×105 cells/well)
were plated over the entire surface of the well. Neurons on one side of the grooves contact the
glial bedlayer, while neurons on other side grow on the culture surface, without direct glial
contact. However, all neurons are exposed to glial conditioned medium. It is hard to visualize the
neurite extensions when neurons are in contact with glia. Thus, for co-culture studies we only
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examined neurons growing on culture surface. Neuron and neuron-glia co-cultures were
similarly maintained in supplemented neurobasal medium. Neurons were allowed to mature for
6-7 d prior to treatment.
Supernatant from HIV-infected cells
H9 and U937 cells (ATCC, Manassas, VA; 0.5 × 105 cells/ml) were cultured in RPMI-1640
medium (Gibco) supplemented with 10% FBS, and stimulated with interleukin-2 (IL-2, 100
ng/ml; Sigma-Aldrich), phytohaemagglutinin (PHA, 5 µg/ml; Sigma-Aldrich), and phorbol 12myristate 13-acetate (PMA, 100 ng/ml; only for U937 cells to induce differentiation; SigmaAldrich), for 48 h. Stimulated cells were treated with polybrene (2 μg/ml; Sigma-Aldrich) for 30
min at 37°C, resuspended in fresh medium and exposed respectively to HIV-1LAI and HIV-1SF162
(p24 = 25-50 pg/ml; X4-tropic, HIV-1LAI, from Dr. Jean-Marie Bechet and Dr. Luc Montagnier
[269, 270], and R5-tropic, HIV-1SF162, from Dr. Jay Levy [215] through NIH AIDS Research and
Reference Reagent Program, Germantown, MD). After 5-7 d, supernatants (HIV+sup) were
collected by filtering through a 0.20-μm filter, and viral productive infection was confirmed by
quantifying HIV-p24 levels using ELISA (Advanced Bioscience Laboratories, Rockville, MD;
typically a 3-5 fold increase in 5-7 d). Supernatants from uninfected/untreated H9 and U937 cells
(Controlsup) were used as a control. Cell culture supernatants were aliquoted and stored at -80°C.
Treatments
Our previous studies have shown that R5-tropic HIV+sup induces neurotoxic effects in a
concentration-dependent manner over a range of p24 levels (10-500 pg/ml). However, the
interactions with morphine were significant only at lower HIV-exposure levels (p24 = 10 and 25
pg/ml) [256]. Accordingly, the present studies used a HIV+sup exposure level of p24 = 25 pg/ml.
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In addition, the neurotoxic effects mediated by purified virus (virus particles or virion; HIVvirion)
at the same p24 exposure level were tested. HIV+sup/Controlsup or HIVvirion were added to
neuronal cultures in the presence or absence of morphine sulfate (morphine; 500 nM; SigmaAldrich) ± naloxone (1.5 µM; Sigma-Aldrich), a general opioid receptor antagonist.
Neuron viability assessments
After treatment, digital images of pre-selected neurons were recorded at 1 h interval for 72 h
using a microscope with computer-regulated stage (Axio Vision 4.6; Zeiss Inc., Thornwood, NY)
and controlled environment (37°C, 95% humidity and 5% CO2). Pre-selected neurons were
visually assessed for viability in digital images at 6 h intervals. Cell death was confirmed using
rigorous morphological criteria, including excessive neurite disintegration, cell body
fragmentation, nuclear destruction and loss of phase brightness [151, 153, 218, 256]. Findings
were reported as average percentage of neuron survival as a proportion of pre-treatment neuron
count ± standard error of the mean (SEM). The effect of each treatment on neuron survival was
analyzed using a repeated measures analysis of variance (ANOVA) followed by Duncan’s post
hoc test (Statistica 8.0; StatSoft, Tulsa, OK).
TUNEL assay
At specified intervals after treatment, cells were rinsed with PBS (Gibco) and fixed overnight at
4°C in 4% paraformaldehyde (Sigma-Aldrich). Cells were permeabilized at room temperature
with 0.1% Triton-X 100 (Molecular Probes) and 0.1% BSA for 15 min, and subsequently
blocked in 0.1% BSA (Invitrogen, Grand Island, NY) and 1% horse serum (Invitrogen) for 30
min. Cells were labeled with Hoechst 33342 (Sigma-Aldrich) and TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end labeling; Roche Applied Sciences, Mannheim,
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Germany). Cells were visualized and digital images were acquired using an Axio Observer Z.1
microscope and Zen 2010 software (Zeiss Inc.). Neuronal apoptosis was assessed by manually
counting the percentage of TUNEL(+) cells in digital images.
Neurite length assessments
At specified intervals after treatment cells were fixed, permeabilized, blocked and subsequently
labeled with TUNEL and MAP-2 (Abcam, Cambridge, MA; ab32454). Cells were visualized and
digital images were acquired. Neurite length was assessed in digital images using modified Sholl
analysis. To specifically evaluate sub-lethal neurite length changes, only TUNEL(-) cells were
examined. Sholl score was calculated by evaluating the cumulative intersections of MAP-2positive neurites with equidistant concentric circles of increasing radius, centered on the cell
body [219]. Sholl score was converted into neurite length in µm using micrometer-scale
calibration.
ELISA
Conditioned medium from HIV-1LAI-infected H9 cells or HIV-1SF162-infected U937 cells
(HIV+sup) and uninfected H9 or U937 cells (Controlsup) were collected at day 5 and assessed for
levels of interleukin 6 (IL-6), tumor necrosis factor α (TNFα), RANTES (also known as CCL5),
and monocyte chemotactic protein-1 (MCP-1, also known as CCL2), using ELISA (R&D
Systems, Minneapolis, MN). 3,3’,5,5’-tetramethylbenzidine (TMB) substrate was added for
color development and plates were read at 450 nm using a PHERAstar microplate reader
immediately after terminating the reaction. Protein levels were determined based on a standard
curve.
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Statistical Analyses
All data were expressed as average ± SEM. Unless otherwise indicated, data were statistically
analyzed using a one-way ANOVA and Duncan’s post hoc test (Statistica 8.0; StatSoft). An α
level of p < 0.05 was considered significant.

Results
Toxic effects of HIV+sup ± morphine in neuron cultures
Cell survival was assessed using time-lapse imaging analysis (Fig. 3.1). In neuron-alone cultures,
over the period of 72 h, HIV+sup significantly reduced neuron survival (Fig. 3.1B; Neuron panel).
HIV+sup-mediated neuron death was significantly enhanced by morphine co-treatment, and the
interactive effect of morphine was blocked by naloxone. Cell death was additionally confirmed
using TUNEL-staining (Fig. 3.2). At all assessed time-points, HIV+sup significantly increased the
percentage of TUNEL(+) neurons, which was augmented by morphine co-treatment (Fig. 3.2;
Neuron panel). Interactive effects of morphine were blocked by naloxone.
Since sublethal synaptic losses and neurite damage are considered to be a principal substrate for
HAND [87-91], changes in neurite lengths were assessed using MAP-2 immunostaining
followed by Sholl analysis (Fig. 3.3). To specifically evaluate sublethal neurite length changes,
only TUNEL(-) cells were assessed instead of whole cell population, where inclusion of dead
cells may distort the findings. In neuron-alone cultures, HIV+sup significantly reduced neurite
lengths at all assessed time-points. No significant morphine interactions were noted (Fig. 3.3B;
Neuron panel).
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Role of glia in HIV+sup ± morphine-mediated neurotoxic effects
HIV-1 itself rarely infects neurons [22, 47, 49, 58]; instead it induces indirect neurotoxic effects
via release of cellular and viral toxic products from infected and activated glial cells [22, 62-65,
251-253]. To assess the role of glia in HIV ± morphine-mediated neurotoxicity all treatments
were carried out either in presence or absence of glia. In the presence of glia, HIV+sup ±
morphine-mediated neuron death was significantly enhanced (Fig. 3.1B and 3.2; compare
panels). The presence of glia did not cause any significant effect on HIV+sup ± morphinemediated neurite pruning (Fig. 3.3B; compare panels). In contrast, Controlsup-treated groups had
significantly longer neurites.
Secretion of cytokines/chemokines from HIV-1-infected T-cells
The ‘indirect injury’ or ‘bystander damage’ hypothesis suggests that cytotoxic factors released
from infected and activated cells cause neuronal injury [22, 62, 63]. Secretion of proinflammatory factors was analyzed by assessing levels of cytokines/chemokines in conditioned
medium from HIV-1LAI-infected H9 cells and HIV-1SF162-infected U937 cells using ELISA (Fig.
3.4). After HIV-1-infection/exposure, with both viral strains, levels of IL-6, TNFα and RANTES
were significantly increased. Infection of U937 cells with HIV-1SF162 caused significant increase
in levels of MCP-1, but no significant change in MCP-1 levels was seen after infection of H9
cells with HIV-1LAI.
HIVvirion ± morphine-mediated neuronal death
Many previous studies have shown that HIV-1 proteins as well as cytotoxic factors released from
infected and activated cells induce neuronal damage [22, 62, 63, 67, 68, 71, 72]. But the
neurotoxic effects produced by the virion itself and their interactions with opiates are not known.
53

HIV-1-virion (HIV-1LAI and HIV-1SF162) and morphine-mediated neuronal death was assessed
using time-lapse imaging analysis (Fig. 3.5). In neuron-alone cultures, over the period of 72 h, no
significant change in cell survival was seen after any treatments (Fig. 3.5; Neuron panel). In
neuron-glia co-cultures, only HIV-1LAI alone significantly reduced neuron survival (Fig. 3.5;
Neuron-glia panel). Both viral strains significantly induced cell death when co-treated with
morphine. Presence of glia significantly increased HIV-1LAI + morphine-mediated effects.

Discussion
The neurotoxic effects and interactions with opiates of HIV-1LAI-supernatant (a X4 tropic strain)
are quantitatively similar to that of HIV-1SF162 (a R5-tropic strain). This suggests that the toxic
effects are largely attributable to cellular factors released from infected and activated cells
instead of viral strain-specific factors. Secretion of certain cytokines/chemokines by H9 cells was
elevated after infection/exposure to HIV-1LAI. Surprisingly, the cytokine/chemokine release
profile of HIV-1LAI-infected H9 cells is almost similar to that of HIV-1SF162-infected U937 cells.
This is the first demonstration that HIV-1LAI-virion alone induces deleterious effects on neurons;
however, this occurs only in the presence of glia. These results extend prior findings regarding
the role of glia in HIV-1 mediated neurotoxicity.
Our results show that opiates interact with and exacerbate HIV+sup-mediated effects that result in
neuronal death. But unlike cell death, opiates did not cause significant effects on HIV+supmediated neurite pruning. From these results it can be interpreted that HIV-1 induces multiple
pathways in neurons that result in different outcomes, and opiates interact with only certain
pathways. HIV-1 alone or in concert with opiates induces release of various neurotoxic factors
from glia [125, 147, 155], they also disturb neuron-supportive functions of glia, such as
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glutamate buffering, free radical scavenging, release of neurotrophic factors and others [153,
155, 248, 249]. Accordingly, our results also showed that HIV ± opiate mediated certain
neurotoxic outcomes were exacerbated in presence of glia. Also severity of neurotoxic
interactions between HIV-1 and opiates were enhanced in presence of glia. But HIV-1 and
opiates showed some significant interactions in absence of glia too. Therefore, it can be
concluded that though glia are important in HIV-1-opiate interactions, some interactions occur
directly upon neurons.
The deleterious effects of HIV-1LAI-supernatant on neurons are quantitatively similar to that of
HIV-1SF162, as previously observed [256]. These results are in conflict with some previous
studies [271, 272], where strain/tropism specific differences in neuropathological profiles have
been seen. Also some previous studies have shown that drugs of abuse interact with HIV-1proteins in strain dependent manner [151, 268]. But in our studies we did not find quantitative
differences between interactions of X4 and R5-tropic viral strain supernatants with opiates.
Disparate findings may reflect the differences in response of neurons to individual viral proteins
versus the multiple stimuli in HIV+sup. Our results suggest that neurotoxic effects mediated by
HIV+sup are mainly attributed to common cytotoxic factors released from infected and activated
cells instead of virion (viral strain) specific factors. These results support the theory that ‘indirect
injury’ hypothesis is predominate over ‘direct injury’ hypothesis [62, 63].
Many previous studies have modeled HIV-1-neuropathalogy using individual viral proteins. But
CNS of HIV-1-infected patients is not only exposed to individual viral proteins instead it is
exposed to all cellular and viral factors and virions released from infected and/or activated cells.
To model disease process more closely we used supernatant from HIV-1-infected cells. ‘Indirect
injury’ or ‘bystander damage’ hypothesis suggest that HIV-1-mediated neurotoxic effects are
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mainly attributed to cellular factors including cytokines, chemokines, excitotoxic factors and free
radicals, released from infected and/or activated cells [22, 62-65, 251-253]. Our results show that
after infection/exposure of H9 cells to HIV-1LAI secretion of certain cytokines including IL-6,
TNFα and RANTES was enhanced. Surprisingly, cytokine/chemokine release profile, for
assessed molecules, of HIV-1LAI-infected H9 cells is almost similar to that of HIV-1SF162-infected
U937 cells; suggests reason behind the similarity between the neurotoxicity profiles of different
viral strain-supernatants. Certain cellular factors are known to play role in HIV-1-mediated
neurotoxicity [82, 273-276]. Although in current studies we have assessed only four
cytokines/chemokines there must be other cellular factors released from infected and activated
cells playing role in HIV-1-mediated neurotoxicity.
Our studies demonstrated that HIVvirion induces neurotoxic effects but only in the presence of
glia. Since we are using murine cell culture model, HIVvirion cannot infect the glia in our cultures.
Thus, it can be predicted that HIVvirion may interact with glia and may induce release of cytotoxic
factors and may also disturbs neuronal supportive functions of glia. These studies support and
extend prior findings regarding the role of glia in HIV-1 mediated neurotoxicity [145, 153, 155,
277]. Though we have used HIV+sup and HIVvirion at same p24 concentration our results show that
HIV+sup is highly neurotoxic than HIVvirion. One of the obvious interpretations for these findings
is that HIV+sup includes HIVvirion as well as cellular and viral factors released from infected and
activated cells. Greater neurotoxic outcomes than seen with HIV+sup can be attributed to cellular
and viral factors secreted from activated and infected cells. Also, the opiate-interactions seen
with HIV+sup are not evident with HIVvirion. The neurotoxic interactions between HIV-1 and
opiates are mainly caused by secreted factors instead of by HIVvirion.
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Though we did not observe quantitative strain/tropism-specific differences in HIV+sup-mediated
neurotoxic outcomes; surprisingly, HIVvirion displayed strain-specific differences. It can be
concluded that in case of HIV+sup, strain specific-effects by HIVvirion are overshadowed by
common secreted factors. Our results indicate that HIV-1LAI is slightly more neurotoxic than
HIV-1SF162. Our results are in accord with some previous studies which also have showed that
X4-tropic viral strains are more neurotoxic than R5-tropic strains [271, 272].
Overall our results show that opiates interact with and exacerbate HIV+sup-mediated effects that
result in cell death in striatal neuron cultures. HIV-1 and opiate mediated selective neurotoxic
outcomes were enhanced in the presence of glia, suggesting role of glia in these processes.
Surprisingly neurotoxic outcomes profile by X4 and R5-tropic HIV-1-supernatants were
quantitatively similar. Since assessed cytokine/chemokine release profile by X4-tropic virus
infected T-cells and R5-tropic virus infected monocytes were almost similar HIV+sup-mediated
neurotoxic outcomes are mainly attributed to cytotoxic factors released from infected and
activated cells. Our results show that X4-tropic virion is slightly more neurotoxic than R5-tropic
virion, may explain why co-receptor usage switch from CCR5 to CXCR4 is crucial in disease
progression [264, 267].
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Figures

Figure 3.1. HIV+sup ± morphine-mediated neuronal death. (A) Cells were repeatedly imaged
for 72 h after treatments; digital images of the same cells/fields at 0, 24 and 72 h (white
arrowheads indicate dead cells that were alive in previous image). (B) Cells were assessed for
viability at 6 h intervals in digital images. The findings were reported as the average percentage
of neuron survival as a proportion of pre-treatment neuron count ± SEM. Significance was
analyzed by repeated measures ANOVA and Duncan’s post hoc test; n = 4 separate experiments
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(at least 150 neurons per treatment group). In both culture systems, HIV+sup significantly reduced
neuronal survival (*p < 0.05 vs. C), which was significantly augmented by morphine cotreatment (#p < 0.05 vs. H). Interactive effects of morphine were blocked by naloxone. In the
presence of glia, HIV+sup ± morphine-mediated neuronal death was significantly enhanced ($p <
0.05 vs. corresponding treatment in neuron-alone cultures; compare panels). C = Controlsup; H =
HIV+sup; M = morphine sulfate; N = naloxone (1.5 µM).

59

Figure 3.2. Neuronal apoptosis induced by HIV+sup ± morphine. Cells were fixed at specific
intervals after treatment and labeled for Hoechst 33342 (blue) and TUNEL (red). The rate of
neuron apoptosis was assessed by counting the percentage of TUNEL(+) cells, and reported as
average % of TUNEL(+) cells ± SEM. Significance was analyzed by one-way ANOVA and
Duncan’s post hoc test; n = 3 separate experiments. At all assessed time points, in both culture
systems, HIV+sup significantly increased % of TUNEL(+) cells (*p < 0.05 vs. respective C
group). Morphine significantly augmented HIV+sup-mediated neuronal apoptosis (#p < 0.05 vs.
respective H group), interactive effects of morphine were blocked by naloxone. In the presence
of glia, HIV+sup ± morphine-mediated neuronal apoptosis was significantly augmented ($p < 0.05
vs. corresponding treatment in neuron cultures; compare panels). C = Controlsup; H = HIV+sup; M
= morphine sulfate; N = naloxone.
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Figure 3.3. HIV+sup ± morphine-mediated neurite damage. Cells were fixed at specific
intervals after treatment and labeled for MAP-2 (green) and TUNEL (red). (A) Digital images of
neuronal cultures at 72 h after treatment. (B) The ‘Sholl score’ was assessed only for TUNEL(-)
neurons in the digital images and converted into neurite length in µm via a micrometer-scale
calibration. The findings were reported as average neurite length per neuron (µm) ± SEM.
Significance was analyzed by one-way ANOVA and Duncan’s post hoc test from n = 3 separate
experiments. At all time-points, in both culture systems, HIV+sup significantly reduced neurite
length (*p < 0.05 vs. C), without any significant morphine interaction. In the presence of glia,
Controlsup-treated groups showed significantly longer neurite length ($p < 0.05 vs. corresponding
treatment in neuron cultures; compare panels). C = Controlsup; H = HIV+sup; M = morphine
sulfate; N = naloxone.
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Figure 3.4. Cytokines/chemokines secretion from HIV-1-infected cells. Conditioned medium
from HIV-1LAI (X4)-infected H9 cells or HIV-1SF162 (R5)-infected U937 cells (HIV+sup) and
uninfected H9 or U937 cells (Controlsup) at day 5 were collected and assessed for levels of IL-6,
TNFα, RANTES and MCP-1, using ELISA. The findings were reported as average
concentrations (pg/ml) ± SEM. Significance was analyzed using a one-way ANOVA and
Duncan’s post hoc test, from n = 3 separate experiments. HIV-1-infection, with both viral strains,
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elevated IL-6, TNFα and RANTES levels (*p < 0.05 vs. Controlsup). Infection of U937 cells with
HIV-1SF162 caused significant increase levels of MCP-1, but no significant change in MCP-1
levels was seen after infection of H9 cells with HIV-1LAI.
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Figure 3.5. HIVvirion ± morphine-mediated neuronal death. Neurons were repeatedly imaged
for 72 h after treatment. Cells were assessed for viability at 6 h intervals in digital images. The
findings were reported as the average percentage of neuron survival with respect to pre-treatment
neuron count ± SEM. Significance was analyzed by repeated measures ANOVA and Duncan’s
post hoc test, from n = 4 separate experiments. In neuron-alone cultures, no significant change in
cell survival was seen after any treatments. In the presence of glia, only HIV-1LAI alone
significantly reduced neuron survival (*p < 0.05 vs. C), while both viral strains significantly
increased cell death when co-treated with morphine. Presence of glia significantly increased
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HIV-1LAI + morphine-mediated neuronal death ($p < 0.05 vs. corresponding treatment in
neuronal cultures; compare respective panels). C = Control (cell culture medium); H = HIVvirion
(pure virus; HIV-1LAI and HIV-1SF162); M = morphine sulfate.
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CHAPTER 4
GSK3β-Activation is a Point of Convergence for HIV- and Opiate-Mediated Interactive
Neurotoxicity.
(This chapter is in preparation to submit for publication)

Introduction
Infection of the central nervous system (CNS) with human immunodeficiency virus-1 (HIV-1)
occurs rapidly after primary peripheral infection [22-24, 278]. HIV-1 can induce a wide range of
CNS deficits, collectively known as HIV-1-associated neurocognitive disorders (HAND); nearly
50% of the HIV-1-infected individuals suffer from HAND [100-103]. Infected and/or activated
glial and immune cells in the CNS release various viral and cellular factors that drive direct and
indirect neuronal toxicity, leading to HAND [22, 62-65]. The advent of combination
antiretroviral therapy (cART) has reduced the severity of HAND, but the prevalence of disease
remains the same [88, 105-107, 111, 113, 254], likely due to longer patient survival [112], the
relatively poor CNS penetrance of available antiretroviral drugs [88, 114], their neurotoxic
effects [115], or a combination of all.
Drug abuse is a major risk factor for HIV infection; nearly 30% of HIV+ patients have a history
of drug abuse involving opiates [125, 127]. A large fraction of HIV+ patients are also exposed to
opiates for treatment of AIDS-related chronic pain syndromes. Opiate drugs of abuse modulate
immune function [132, 140, 255], and studies also have shown that opiates promote HIV-1
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replication in vitro [135, 217]. Thus, opiate abuse not only increases the risk of HIV-infection
but may also exacerbate disease progression. Since opiates by themselves have outcomes
involved in neuronal dysfunction, such as blood brain barrier breakdown, immune and glial cell
activation, and neuronal damage [139, 140, 154, 158], it can be predicted that opiate drug abuse
might exacerbate HIV-1 pathogenesis in the CNS. Our previous work has shown that certain
neurotoxic effects induced by the individual HIV-1 proteins, trans-activator of transcription (Tat)
and glycoprotein 120 (gp120) [148, 149, 151-153], and by HIV+ supernatant (HIV+sup) [256], are
enhanced by co-exposure to morphine, the major metabolite of heroin in the CNS [216]. This
mimics co-morbid neurological effects observed in opiate-abusing HIV+ patients [160, 161].
Although there is a correlation between opiate drug abuse and HAND progression, the
mechanisms that underlie interactions between HIV-1 and opiates remain obscure; the main aim
of this work was to identify point(s) of convergence for HIV-1 and morphine signaling in
neurons.
Identified originally as a regulator of glycogen metabolism, glycogen synthase kinase-3β
(GSK3β) is a central component of various signaling pathways in neurons including those
affecting neuronal plasticity, gene expression, and cell survival [163, 165, 173]. Dysregulated
GSK3β activity appears to be operant in various neuropathological conditions, including
Alzheimer’s disease, Parkinson’s disease, schizophrenia, autism, and bipolar mood disorder, and
pharmacological inhibition of GSK3β can ameliorate these diseases [163, 169, 173, 175, 176,
180-183]. Previous studies have shown that HIV-1 induces neurotoxic effects through abnormal
activation of GSK3β [174, 184-188], and that GSK3β is also linked to neuropathology seen with
opiate-abusing patients [141, 142]. We therefore tested GSK3β-activation as a point of
convergent signaling for interaction between HIV-1 and morphine.
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Both lethal and sublethal effects of HIV+sup ± morphine treatments on neurons were assessed in
populations, and also by time-lapse imaging of individual cells over 72 h. Multiple GSK3β
inhibitors significantly reduced HIV-1-mediated neurotoxic outcomes, and also negated
interactions with morphine that resulted in cell death.

Materials and Methods
All experimental procedures were reviewed and approved by the Virginia Commonwealth
University Institutional Animal Care and Use Committee.
Striatal neuron cultures
Our culture model system uses striatal neurons because the striatum is a principal target of HIV1 and levels of opioid receptors in the striatum are relatively high [239, 240, 261]. Mouse striatal
neurons were cultured as previously described [151, 153, 256, 279]. In brief, striata from E15E16 ICR (CD-1) mice (Charles River Laboratories International, Inc., Wilmington, MA) were
dissected, minced and incubated with trypsin (2.5 mg/ml; Sigma-Aldrich, St. Louis, MO) and
deoxyribonuclease (DNase; 0.015 mg/ml; Sigma-Aldrich) in neurobasal medium (Gibco, Grand
Island, NY) for 30 min at 37°C. Tissue was resuspended in neurobasal medium supplemented
with B-27 additives (Gibco), L-glutamine (0.5 mM; Gibco), glutamate (25 µM; Sigma-Aldrich)
and Antibiotic-Antimycotic (Gibco), triturated, and filtered twice through 70 μm nylon mesh
pore filters (BD Biosciences, San Jose, CA). Cells were seeded into culture plates (Corning Inc.,
Corning, NY) pre-coated with poly-L-lysine (0.5 mg/ml; Sigma-Aldrich), in supplemented
neurobasal medium. Purity was determined by immunostaining for microtubule-associated
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protein 2 (MAP-2, a dendrite marker; Abcam, Cambridge, MA; ab32454), and cultures were
found to be > 80% neurons.
HIV supernatants
Cells of the acute monocytic leukemia cell line, THP1 (ATCC, Manassas, VA) were cultured at
0.5 × 105 cells/ml in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum
(FBS; Gibco) and 100 U/ml Penicillin-Streptomycin (Gibco), and stimulated with interleukin-2
(IL-2; 100 ng/ml; Sigma-Aldrich) and phytohaemagglutinin (PHA; 5 μg/ml; Sigma-Aldrich), for
48 h. Stimulated cells were treated with polybrene (2 μg/ml; Sigma-Aldrich) for 30 min at 37°C,
resuspended in fresh medium and exposed to HIV-1SF162 (p24 = 25-50 pg/ml; a R5-tropic HIV-1
strain; from Dr. Jay Levy [215], through NIH AIDS Research and Reference Reagent Program,
Germantown, MD). After 5 d, supernatants (HIV+sup) were collected by filtering through a 0.20μm filter, and viral infection was confirmed by quantifying HIV-p24 levels using ELISA
(Advanced Bioscience Laboratories, Rockville, MD; typically a 3-5 fold increase in 5 d).
Supernatants from uninfected/untreated THP1 cells (Controlsup) were used as a control. Cell
culture supernatants were aliquoted and stored at -80°C.
Treatments
As opiates can enhance HIV replication [135, 217, 280], we assessed the interactive effects of
morphine with cell-free, viral supernatant. Our previous studies showed that supernatants from
HIV-infected cells induce neurotoxic effects in a concentration-dependent manner over a range
of p24 levels (10-500 pg/ml), but the interactions with morphine were significant only at lower
HIV-exposure levels (p24 = 10 and 25 pg/ml) [256]. Current studies used HIV+sup exposure level
of p24 = 25 pg/ml. HIV+sup and Controlsup were added to neuronal cultures in the presence or
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absence of morphine (morphine sulfate; Sigma-Aldrich), at a dose that maximally stimulate
neuronal and glial μ-opioid receptors (MORs) in vitro (500 nM) [145, 147, 149, 151, 153, 220,
221, 256]. To determine the role of GSK3β in HIV- and opiate-mediated neurotoxicity, HIV+sup
± morphine treatments were carried out either in the presence or absence of a standard GSK3β
inhibitor, sodium valproate (valproic acid, VPA; 1 mM; Sigma-Aldrich), or one of two small
molecule inhibitors, SB415286 (10 µM; Sigma-Aldrich) and GSK3β inhibitor XXVI (XXVI; 1
µM; EMD Millipore, Billerica, MA).
TUNEL assay
Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) overnight at 4°C, permeabilized in
0.1% Triton-X 100 (Molecular Probes) and 0.1% BSA (Invitrogen, Grand Island, NY) for 15
min, blocked in 0.1% BSA (Invitrogen, Grand Island, NY) and 1% horse serum (Invitrogen) for
30 min, and subsequently labeled with Hoechst 33342 (Sigma-Aldrich) and TUNEL (terminal
deoxynucleotidyl transferase dUTP nick end labeling; Roche Applied Sciences, Mannheim,
Germany). Cells were visualized and digital images were acquired using the Axio Observer Z.1
microscope and Zen 2010 software (Zeiss Inc., Thornwood, NY). Neuronal apoptosis was
assessed by manually counting the percentage of TUNEL(+) cells.
Assessment of neuron viability
Time-lapse digital images of pre-selected neurons were captured at 1 h interval for 72 h after
treatments using a microscope with computer-regulated stage (Axio Vision 4.6; Carl Zeiss Inc.)
and controlled environment (37°C, 95% humidity, 5% CO2). In digital images, neurons were
assessed for viability at 6 h intervals using rigorous morphological criteria confirming cell death,
including cytoplasmic swelling, nuclear destruction, cell body fragmentation, excessive neurite
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degeneration, and loss of phase brightness [151, 153, 218, 256, 279]. Findings were reported as
the average percentage of neuronal survival, with respect to pre-treatment neuron count ±
standard error of the mean (SEM). The effect of each treatment on neuronal survival was
analyzed using a repeated measures analysis of variance (ANOVA) followed by Duncan’s post
hoc test (Statistica 8.0; StatSoft, Tulsa, OK) from n = 3-5 experiments (at least 50 neurons per
treatment group per experiment; total, 150-250 neurons per treatment group).
Assessment of neuritic arborization
Cells were fixed, permeabilized, blocked, and subsequently labeled for MAP-2 (Abcam),
TUNEL (Roche Applied Sciences), and Hoechst 33342 (Sigma-Aldrich). Cells were visualized
and digital images were acquired. Neuritic arborization was evaluated using Sholl analysis; a
‘Sholl score’ was measured by counting the number of intersections of MAP-2-positive neurites
with equidistant concentric circles of increasing radius, centered on the cell body [219]. To avoid
the inclusion of dead cells, we specifically evaluated neuritic arborization changes by including
only TUNEL(-) cells in our assessments.
Immunoblotting
Whole cell extracts were prepared using radioimmunoprecipitation assay (RIPA) buffer (SigmaAldrich) with protease and phosphatase inhibitors (Roche Applied Sciences), and total protein
concentrations were determined by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific,
Rockford, IL). Cell lysates containing equal amounts of total protein (~5-10 μg) were heated at
100º C for 5 minutes in laemmli buffer (Sigma-Aldrich), electrophoretically separated on a 10%
SDS-polyacrylamide gels (Bio-Rad, Hercules, CA), and transferred onto polyvinylidene
difluoride (PVDF) membranes (Bio-Rad). Membranes were incubated with primary antibodies to
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phospho-GSK3β-Ser9 (Cell Signaling Technology, Danvers, MA; 5558), GSK3β (Cell Signaling
Technology; 9832), β-Catenin (Cell Signaling Technology; 9562), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; Abcam; ab8245), MAP-2 (Abcam; ab32454) and postsynaptic density
protein 95 (PSD-95; UC Davis/NIH NeuroMab Facility, Davis, CA; 73-028). Appropriate
horseradish peroxidase-conjugated secondary antibodies (SouthernBiotech, Birmingham, AL)
were used. Membranes were detected using SuperSignal® West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific), and visualized using a Kodak Image Station 440CF.
Statistical Analyses
All data were expressed as average ± SEM. Unless otherwise indicated, data were analyzed
statistically using a one-way ANOVA followed by Duncan’s post hoc test using Statistica 8.0
(StatSoft); an α level of p < 0.05 was considered significant.

Results
HIV- and morphine-mediated GSK3β activation
GSK3β activation/inactivation was assessed at 4 h after treatments. Cell lysates were
immunoblotted for phospho-GSK3β-Ser9 (p-GSK3β-S9; an inactive form of GSK3β [165, 173,
175, 233]), GSK3β (total GSK3β; t-GSK3β), β-Catenin, and GAPDH (Fig. 4.1). HIV+sup, with or
without morphine, significantly decreased p-GSK3β-S9 (normalized with t-GSK3β; p-GSK3βS9/t-GSK3β; Fig. 4.1A), suggesting an increase in GSK3β activation. VPA significantly
abrogated HIV+sup ± morphine-mediated effects. β-Catenin is a downstream target of GSK3β;
active GSK3β phosphorylates β-Catenin and initiates rapid ubiquitin-mediated degradation by
the proteasome [173, 175, 189]. HIV+sup, with or without morphine, significantly reduced β72

Catenin levels (Fig. 4.1B), suggesting an enhancement in GSK3β activity. VPA completely
inhibited the effect of HIV+sup + morphine and partially inhibited the effect of HIV+sup alone,
returning both to levels that were not different from control levels.
Opiates are known to induce time-dependent effects on GSK3β activation [205, 206]. Since
significant individual or interactive effects of morphine were not detected at 4 h, HIV+sup and
morphine-mediated effects were assessed at longer time intervals (Fig. 4.2). At all assessed time
points (12, 24, and 72 h), HIV+sup significantly reduced p-GSK3β-S9. At 24 and 72 h, morphine
alone also induced significant loss of p-GSK3β-S9, but a significant interaction with HIV+sup was
seen only at 24 h.
Role of GSK3β in HIV ± morphine-mediated cell death
Neurons exposed to morphine and/or VPA had survival values equivalent to control, while all
groups treated with HIV+sup showed significantly reduced neuronal survival (time-lapse imaging
analysis; Fig. 4.3B). Morphine significantly enhanced HIV+sup-mediated neuronal death. HIV+sup
± morphine-mediated effects were partially, but significantly, reversed by VPA co-treatment.
The survival of neurons treated with ‘HIV+sup + VPA’ and ‘HIV+sup + morphine + VPA’ was not
significantly different, showing that VPA effectively negated any HIV+sup-morphine interactions.
Cell death was additionally confirmed using TUNEL staining (Fig. 4.3C). HIV+sup induced a
significant increase in TUNEL(+) neurons, which was augmented by morphine co-treatment.
HIV+sup ± morphine-mediated effects were partially, but significantly, reversed by VPA cotreatment. As seen for the time-lapse analyses, VPA also nullified the interactions between
HIV+sup and morphine.
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Role of GSK3β in HIV ± morphine-mediated changes in neuritic arborization, MAP-2 and
PSD-95
Since neurite degeneration and synapse losses are the major substrate for HAND [87-91] we
assessed changes in neuritic arborization using MAP-2 immunostaining followed by Sholl
analysis (Fig. 4.4A and B). At 72 h, HIV+sup induced a significant reduction in neuritic
arborization (Fig. 4.4B). There was no morphine interaction, and the HIV effect was partially,
but significantly, reversed by VPA co-treatment. Neuritic/synaptic degeneration was additionally
confirmed by immunoblotting for MAP-2 and PSD-95 (Fig. 4.4C and D). At 72 h, HIV+sup
significantly decreased MAP-2. Similar to the Sholl analysis, there was no morphine interaction
(Fig. 4.4C), and VPA significantly abrogated HIV+sup-mediated loss of MAP-2. HIV+sup also
induced a significant loss in PSD-95, but in this case there was an increased loss with morphine
co-treatment (Fig. 4.4D). VPA partially, but significantly, reversed HIV+sup ± morphine effects
on PSD-95. The HIV-morphine interaction on PSD-95 levels was maintained in the presence of
VPA.
Effects of small molecule GSK3β-inhibitors
The role of GSK3β activation in HIV+sup ± morphine-mediated neurotoxicity was confirmed by
the additional use of the small molecule GSK3β-inhibitors, SB415286 or XXVI (Fig. 4.5). Both
small molecule inhibitors partially, but significantly, reduced HIV+sup ± morphine-mediated
neuronal death, and also abrogated HIV+sup-morphine interactions (Fig. 4.5A and B). Both
inhibitors reversed the effect of HIV+sup on neurite loss, although SB415286 only resulted in
partial recovery (Fig. 4.5C).
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Discussion
The current studies show that GSK3β inhibitors reduce many neurotoxic effects of HIV+sup ±
morphine, including cell death, neurite pruning, and loss of structural and functional proteins,
indicating that GSK3β plays an active role in multiple, degenerative processes. Interactions
between HIV+sup and morphine enhanced neuronal death and increased the loss of PSD95,
similar to interactions that we have previously reported for HIV proteins and morphine [148,
149, 151-153]. Importantly, GSK3β-inhibitors entirely negated the HIV-morphine interactive
effect on neuron death, demonstrating for the first time that GSK3β-activation is an important
point of convergence for neurotoxic interactions between HIV and opiates. GSK3β-inhibitors
only partially reversed certain effects of HIV+sup, and did not disrupt HIV-morphine interactive
effects on PSD95, indicating the likely involvement of other signaling pathways in various
aspects of HIV± morphine-related neurotoxicity.
Though HIV-1 induces profound changes in neuronal morphology, function, and survival, the
virus itself rarely infects neurons [22, 47, 49, 58]; instead, infected and activated glial cells
produce cellular and viral products that drive secondary toxicity in neurons, known as ‘bystander
damage’ [22, 62-65]. Our previous studies have shown that glia play a crucial role in
determining the extent of neurotoxic interactions between the HIV-1 proteins, Tat or gp120 and
opiates [151, 153] as well as those between supernatant from HIV-1 infected cells and opiates
[256]. As the present studies primarily focus on understanding the pathway(s) in neurons that
underlie HIV-1 and opiate interactions, we excluded glia from our culture model system. Still, it
must be remembered that glial mechanisms play important roles in HIV- and opiate-mediated
neurotoxicity.
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In accord with many previous studies [174, 184-188], our results show that HIV+sup induces
GSK3β-activation, and that treatments to inhibit GSK3β activation ameliorate HIV+sup-mediated
neurotoxic effects. GSK3β-activation clearly plays a central role in HIV-1-associated neuronal
damage. Abnormally active GSK3β can promote neuronal damage via dysregulating
function/stability of various structural, metabolic, and signaling proteins, including tau, βcatenin, MAP-2, activator protein 1 (AP-1), cyclic AMP response element binding protein
(CREB), nuclear factor-kappa B (NF-κB), heat shock factor-1 (HSF-1), and others. [163, 165,
166, 175]. In our study, certain neurotoxic outcomes due to HIV+sup were only partially reversed
by co-treatment with GSK3β inhibitors, suggesting the involvement of other factors such as
mitogen-activated protein kinase 10 (MAPK10), double-stranded RNA-activated protein kinase
(PKR), and cyclin-dependent kinase 5 (CDK5) [174, 281, 282].
Studies from the brains of opiate-abusing patients have indirectly implicated GSK3β-activation
in opiate-associated neuropathology [141, 142]. However, previous studies have disagreed on
whether opiates induce GSK3β activation [205, 206] or cause inactivation [208, 209]. Opiates
induce effects on GSK3β-activity in a dose- and time-dependent manner [206]. Acute activation
of µ-opioid receptors (MORs) inhibits GSK3β activity via phosphatidylinositol 3 kinase
(PI3K)/Akt signaling pathway [209], while chronic activation of MORs elevates GSK3β activity
[205, 206], may be through transient increase in intracellular calcium [205, 283, 284]. In accord
with these studies, our results also show that morphine exerts time-dependent effects on GSK3β
activation (Fig. 4.1 and 4.2). At earlier time points (4 and 12 h) morphine effects were not
observed, but at later time points (24 and 72 h) morphine significantly induced GSK3β
activation.
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At 24 h, morphine significantly augmented HIV+sup-mediated GSK3β activation (Fig. 4.2), but
this transient additive/interactive effect of morphine was not seen at 72 h. By 72 h, HIV+sup +
morphine treatment induced nearly 50% cell death (Fig. 4.3 and 4.5). Therefore, may be due to
excessive cell death or selective loss of MOR-expressing neurons interactive effect of morphine
is vanished. Though at 72 h, no significant interactive effect of morphine was seen, overall
tendency of morphine is to induce GSK3β activation.
Although there was no additive/interactive effect of morphine on p-GSK3β at 72 h, morphine did
exacerbate some neurotoxic effects of HIV+sup at that time (cell death and loss of PSD-95). This
discordance may be due to a difference in the time-frame of the ‘cause’ and the ‘effect’. The
morphine-mediated interactive elevation in GSK3β activity seen at 24 h is the cause, resulting in
an ‘effect’, aggravation of neurotoxic outcomes that is seen at a somewhat later time.
Certain neurotoxic outcomes of HIV+sup were completely reversed by VPA co-treatment (loss of
MAP-2; Fig. 4.4C), while some were only partially reversed (cell death and loss of PSD-95; Fig.
4.3 and 4.4D). In terms of HIV+sup-morphine interactions, VPA co-treatment negated the
interaction that augmented neuronal death (Fig. 4.3), but did not reduce the interaction that
augmented PSD-95 loss (Fig. 4.4D). These discrepancies likely reflect the role(s) of other
molecules or pathways, which, given the multiple downstream pathways and events triggered by
opiates, HIV virions, and factors secreted from HIV-infected cells, is predictable. For example,
CDK5, like GSK3β, is known to be involved in both HIV- and opiate-associated neuropathology
[141, 174, 207, 281, 285], and might be a likely candidate in this regard.
In previous studies, VPA has significantly ameliorated HIV-mediated neurotoxic outcomes both
in experimental models [174, 184, 204] and in patients [203]. Though VPA is a potent GSK3β
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inhibitor, it is not a specific inhibitor; VPA targets additional molecules/pathways, including
HDAC, Na+ channels, Ca2+ channels, voltage-gated K+ channels, GSK3α, and others [286].
Therefore, we also tested effects of the small molecule GSK3β-inhibitors SB415286 and XXVI
which have much greater target specificity. Since both small molecule inhibitors similarly
inhibited HIV+sup ± morphine-mediated neurotoxic outcomes (Fig. 4.5), the role of GSK3β in
these processes is confirmed.
HIV+ patients who abuse opiates show more serious neuropathologies and behavioral and
cognitive deficits [160, 161]. The current work implies that GSK3β-mediated signaling
pathway(s) are mechanistic in HIV-opiate interactions. Our recent studies have shown that the
continuous presence of morphine limits the ability of neurons to recover from an HIV insults,
even after HIV is removed [256]. In the post-cART era those studies are quite critical because
they suggest that continual exposure to opiate drugs of abuse, and perhaps also opiates
prescribed for pain, can limit the reversibility of HIV insults in the CNS. If true, this will impact
the effectiveness of neurotherapeutic efforts. Based on the current findings it is reasonable to
predict that opiates might limit neurite recovery after HIV insults via a GSK3β-mediated
signaling mechanism. A recent study by Kehn-Hall et al. has shown that 6BIOder, a novel
GSK3β-inhibitor, inhibits HIV-1 replication [201]. Also GSK3β is identified as a central
mediator of pro-inflammatory processes in CNS [169, 198-200]. Thus, therapeutically targeting
GSK3β along with cART may further diminish viral replication, neuroinflammation and
neuronal damage, and may improve recovery.
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Figures

Figure 4.1. HIV+sup ± morphine-mediated GSK3β activation. At 4 h after treatment, cells
were lysed and protein levels were detected using immunoblot analysis. Findings were reported
as average normalized protein levels (% control) ± SEM. Significance was analyzed by one-way
ANOVA and Duncan’s post hoc test; n = 4 separate experiments. (A) Immunoblotting for
phospho-GSK3β-Ser9 (p-GSKβ-S9) and total GSK3β (t-GSK3β); levels of p-GSKβ-S9 were
normalized with t-GSK3β (p-GSKβ-S9/t-GSK3β). HIV+sup significantly reduced p-GSK3β-S9
(*p < 0.05 vs. Control), without any significant morphine interaction. VPA significantly
abrogated HIV+sup ± morphine-mediated effects (#p < 0.05). (B) Immunoblotting for β-catenin
and GAPDH; levels of β-catenin were normalized with GAPDH (β-catenin/GAPDH). HIV+sup
significantly decreased β-catenin (*p < 0.05 vs. Control) without any morphine interaction. VPA
restored β-catenin levels to control values (#p < 0.05), although in the case of neurons treated
with HIV+sup alone the effect was somewhat less significant (HIV + VPA was not different from
either HIV or control). Control = controlsup; HIV = HIV+sup; Mor = morphine sulfate; VPA =
sodium valproate.
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Figure 4.2. HIV+sup- and morphine-mediated interactive effects on GSK3β-activation. At
12, 24 and 72 h after treatment, cells were lysed and immunoblotted for p-GSKβ-S9 and tGSK3β. Findings were reported as average levels of p-GSKβ-S9 normalized with t-GSK3β (pGSKβ-S9/t-GSK3β) as a percentage of control values ± SEM. Significance was analyzed by oneway ANOVA and Duncan’s post hoc test; n = 3 separate experiments. At all times, HIV+sup
significantly reduced p-GSK3β-S9 (*p < 0.05 vs. Control). At 24 and 72 h, morphine alone also
induced significant loss of p-GSK3β-S9. A significant interaction with HIV+sup was seen at 24 h
($p< 0.05). Control = controlsup; HIV = HIV+sup; Mor = morphine sulfate.
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Figure 4.3. Role of GSK3β in HIV+sup ± morphine-mediated cell death. (A) Cells were
repeatedly imaged for 72 h after treatments. Digital images show the same cells/fields at 0, 24
and 72 h (white arrowheads indicate dead cells that were alive in previous image). (B) Cells were
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assessed for viability at 6 h intervals in digital images. Findings were reported as the average
percentage of neuronal survival as a proportion of pre-treatment neuron count ± SEM.
Significance was analyzed by repeated measures ANOVA and Duncan’s post hoc test; n = 3
separate experiments (at least 150 neurons per treatment group). HIV+sup significantly reduced
neuronal survival (*p < 0.05 vs. Control), which was significantly augmented by morphine cotreatment ($p < 0.05). HIV+sup ± morphine-mediated effects were partially, but significantly,
reversed by VPA (#p < 0.05). VPA also effectively negated HIV+sup-morphine interactions. (C)
At 72 h after treatment, cells were fixed, permeabilized, and labeled for TUNEL and Hoechst
33342. The rate of neuronal apoptosis was reported as the average percentage of TUNEL(+) cells
± SEM. Significance was analyzed by one-way ANOVA and Duncan’s post hoc test; n = 3
separate experiments. HIV+sup significantly increased the percentage of TUNEL(+) cells (*p <
0.05 vs. Control), and morphine augmented the effect ($p < 0.05). HIV+sup ± morphine-mediated
effects were partially, but significantly, reversed by VPA co-treatment (#p < 0.05), and VPA
negated interactions between HIV+sup and morphine. Control = controlsup; HIV = HIV+sup; Mor =
morphine sulfate; VPA = sodium valproate.
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Figure 4.4. Role of GSK3β in HIV+sup ± morphine-mediated changes in neuritic
arborization, MAP-2 and PSD-95. (A) At 72 h after treatment, cells were fixed, permeabilized,
and labeled for MAP-2 (green), TUNEL (red) and Hoechst 33342 (blue) (B) Neurite arborization
was measured by Sholl analysis in digital images of TUNEL(-) neurons. The findings were
reported as average Sholl score ± SEM. HIV+sup significantly reduced the Sholl score (*p < 0.05
vs. Control), without any significant morphine interaction. HIV+sup ± morphine-mediated effects
were partially, but significantly, reversed by VPA co-treatment (#p < 0.05). (C) At 72 h after
treatments, cells were lysed and immunoblotted for MAP-2 and GAPDH. Findings were reported
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as average normalized MAP-2 (% control) ± SEM. HIV+sup, with or without morphine,
significantly reduced MAP-2 (*p < 0.05 vs. Control). VPA significantly inhibited HIV+sup ±
morphine-mediated effects (#p < 0.05). (D) Cell lysates were immunoblotted for PSD-95 and
GAPDH. Findings were reported as average normalized PSD-95 (% control) ± SEM. HIV+sup
induced a significant loss of PSD-95 (*p < 0.05 vs. Control), which was augmented by morphine
co-treatment ($p < 0.05). HIV+sup ± morphine-mediated effects were partially, but significantly,
reversed by VPA co-treatment (#p < 0.05). Even in the presence of VPA, morphine significantly
augmented the effects of HIV+sup-mediated effects ($p < 0.05). In all studies, significance was
analyzed by one-way ANOVA and Duncan’s post hoc test, from n = 3 separate experiments.
Control = controlsup; HIV = HIV+sup; Mor = morphine sulfate; VPA = sodium valproate.
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Figure 4.5. Effects of small molecule GSK3β-inhibitors. (A) Cell viability was assessed by
time-lapse imaging analysis. Neurons exposed to ‘Control + SB’, ‘Control + XXVI’, ‘Mor’,
‘Mor + SB’ and ‘Mor + XXVI’ treatments had survival equivalent to ‘Control’ but are not
shown in the figure to highlight other groups. HIV+sup significantly reduced neuronal survival (*p
< 0.05 vs. Control), with a significant morphine interaction ($p < 0.05). The effects of HIV+sup
were partially, but significantly, reversed by both small molecule inhibitors (#p < 0.05 vs.
respective HIV or HIV + Mor). Both SB415286 and XXVI also effectively negated interactions
between HIV+sup and morphine. (B) Cell death was examined using TUNEL-staining. HIV+sup
significantly increased the percentage of TUNEL(+) cells (*p < 0.05 vs. Control), with a
significant morphine interaction ($p < 0.05). Both small molecule inhibitors partially reversed
HIV+sup ± morphine-mediated effects (#p < 0.05) and also eradicated the HIV+sup-morphine
interaction. (C) Neuritic arborization was evaluated using MAP-2 immunostaining and Sholl
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analysis. HIV+sup significantly reduced the Sholl score (*p < 0.05 vs. Control) without a
morphine interaction. All losses in arborization were partially, but significantly, reversed by both
small molecule inhibitors (#p < 0.05), except that XXVI completely reversed the effect of
HIV+sup. Control = controlsup; HIV = HIV+sup; Mor = morphine sulfate; SB = SB415286; XXVI =
GSK3β inhibitor XXVI.
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CHAPTER 5
Conclusions

HIV-1 disturbs normal immune system functioning and leads to AIDS. Soon after initial
systemic infection HIV-1 can crossover BBB and enter into CNS [22-24, 278]. HIV-1 can induce
a wide range of neurocognitive deficits, collectively known as HAND. Nearly 50% of HIV-1+
patients suffer from HAND [100-103]. After the advent of cART, the survival rates and health
status of AIDS patients has been tremendously improved [105, 111, 112]. Though cART has
reduced the severity of HIV-associated CNS deficits, the overall prevalence of the disease
remains the same [88, 105-107, 111].
Injection drug abuse is a major cause of acquiring HIV-infection. Nearly 50% of HIV+-patients
have a history of drug abuse, commonly involving opiates [125, 127]. Opiate abusing HIV+patients have high risk for faster progression of AIDS [132, 135, 140, 217, 255]. Many
experimental evidences have shown that opiates exacerbate HIV-1-mediated neurotoxic
outcomes on CNS cells and tissues [125, 145, 147-151, 153], mimics co-morbid neurological
deficits observed in opiate abusing HIV+-patients [160, 161]. Though many experimental and
epidemiological findings have indicated a link between opiate drug abuse and HAND
progression, the extent to which opiates exacerbate neurological deficits is still controversial.
In our current studies, we have tried to determine: (a) whether opiates have any effect HIV-1mediated neurotoxic outcomes; (b) strain/tropism-specific differences in HIV-1 mediated
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neurotoxicity and interactions with opiates; (c) point(s) of convergence for HIV-1 and opiate
mediated signaling.
Many previous studies have modeled HIV-1-mediated neuropathology using individual viral
proteins. But the CNS of HIV-1-infected patients is not only exposed to individual viral proteins
instead it is exposed to all cytotoxins, virotoxins and virus particles released from infected and/or
activated cells. To model disease process more closely, we have used supernatant from HIV-1infected cells. R5-tropic HIV-1 strains are predominant in CNS [213, 214]. Therefore, in chapter
2 we used a R5-tropic strain, HIV-1SF162. We assessed different neurotoxic outcomes mediated
by HIV+sup, in the presence or absence of morphine.
Our results showed that HIV+sup induce neuronal death in concentration-dependent manner. But
interestingly, significant interactive effects of morphine were seen only at lower HIV-1 exposure
levels. Interactive effects of morphine may get masked due to excessive cell death at higher HIV1 exposure levels. These results may explain controversy concerning the role of opiates in
severity of HAND. In addition, our results caution that patients receiving cART may be highly
vulnerable to opiate interactions since cART has greatly reduced the viral load [105, 111, 112].
Our results showed that opiates interact with and exacerbate only selective neurotoxic outcomes
by HIV-1 (compare neuronal death and neurite pruning results). Suggesting that HIV- and
opiate-mediated neurotoxicity is induced via multiple pathways that may lead to different
outcomes, and interactions occur for selective pathways only. Importantly, our results showed
that morphine limits neurite recovery after HIV-1-insults. Altogether, our results suggest that
continual exposure to opiate drugs of abuse may adversely impact the neurotherapeutic efforts of
cART.
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Glia played dual role in HIV-1-mediated neurotoxicity. On one hand, HIV-1 ± morphinemediated neuronal death was exacerbated in presence of glia; by contrast, glia enhanced neurite
outgrowth when HIV was removed. Damaging effects by glia in presence of HIV-1 are largely
attributable to the enhanced release of pro-inflammatory cytokines, and neurotrophic effects after
removal of HIV may due to the rebound in release of growth factors.
We propagated HIV-1 in human cell lines, but due to inconsistency in availability of human
brain cells from specific regions, we used murine cell culture model system. Therefore, we need
to keep in mind the issue of species mixing while interpreting results from our model system.
Cell culture model systems are easy to maintain and manipulate and provide a general idea about
actual in vivo system. However, we need to be cautious when extrapolating these results because
there are various additional factors present in actual in vivo system which may interfere with
these processes.
Though during early stage of infection R5-tropic HIV-1 strains are predominant during late stage
of disease X4-tropic strains are predominant; co-receptor usage switch from CCR5 to CXCR4 is
crucial in disease progression to AIDS [263-267]. Some previous studies have shown that HIV-1
induces neurotoxic effects and interacts with drugs of abuse in strain/tropism-specific manner
[151, 268, 271, 272]. Therefore, in chapter 3 we tried to compare neurotoxic effects of HIV-1LAI
(X4-tropic) and HIV-1SF162 (R5-tropic) and their interactions with opiates.
Surprisingly, our results showed that the neurotoxic effects and interactions with opiates by X4
and R5-tropic HIV-1-supernatants are quantitatively similar. Also cytokine/chemokine release
profile of X4 and R5-tropic HIV-1-infected cells is almost similar. Altogether our results suggest
that HIV-1-supernatant mediated neurotoxicity is mainly attributed to common cytotoxic factors
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released from infected and/or activated cells instead of viral strain specific factors. Our results
support ‘indirect injury’ or ‘bystander damage’ hypothesis.
Interestingly, studies with HIV-1 virion showed strain-specific differences. May be in case of
HIV-1-superntant these strain-specific differences are overshadowed by other cytotoxic factors.
But in case of HIV-1 virion neuronal death was observed in the presence of glia only, confirms
role of glia/glia-activation in HIV-1 mediated neurotoxicity. In accord with some previous
studies [271, 272] our results showed that HIV-1LAI (X4-tropic) is slightly more neurotoxic than
HIV-1SF162 (R5-tropic); these results may explain why co-receptor usage switch is crucial in
disease progression [264, 267].
Though many previous studies have indicated a link between opiate drug abuse and HAND
progression [125, 145, 147-151, 153, 160, 161], the mechanisms that underlie interactions
between HIV-1 and opiates remain largely obscure. Previous studies have shown that HIV-1
induces neurotoxic effects via abnormal activation of GSK3β [174, 184-188], GSK3β is also
linked to neuropathology seen in opiate abusing patients [141, 142]. Therefore, in chapter 4, we
tested role of GSK3β as a point of convergence for interactions between HIV-1 and morphine.
Our results showed that HIV-1 induces GSK3β activation; morphine alone and in concert with
HIV-1 induced GSK3β activation in time-dependent manner. Multiple GSK3β-inhibitors
significantly reduced HIV-1 ± morphine-mediated neurotoxic outcomes, suggesting role of
GSK3β in these processes. Importantly, GSK3β-inhibitors negated selective neurotoxic
interactions between HIV-1 and morphine. Since certain neurotoxic outcomes and interactive
effects were only partially reversed also the role of other factors, such as CDK5, is suggested.
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Altogether our results suggest that GSK3β is a potential therapeutic target for HIV-1- and opiatemediated neurocognitive deficits.
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